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ABSTRACT
Antibacterial and Antifungal Activity of Ceragenins, Mimics of
Endogenous Antimicrobial Peptides
Marjan Mohammadihashemi
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
The continuous emergence of drug-resistance pathogens is a global concern. As a result,
substantial effort is being expended to develop new therapeutics and mechanisms for controlling
microbial growth to avoid entering a “post-antibiotic” era in which commonly used antibiotics are
no longer effective in treating infections. In this work, we investigate the efficacy and application
of ceragenins as non-peptide mimics of antimicrobial peptides (AMPs).
First, this work examines the susceptibility of drug-resistant Gram-negative bacteria. The
susceptibility of colistin-resistant clinical isolates of Klebsiella pneumoniae to ceragenins and
AMPs suggests that there is little to no cross-resistance between colistin and ceragenins/AMPs.
Furthermore, Lipid A modifications are found in bacteria with modest changes in susceptibility to
ceragenins and with high levels of resistance to colistin. Next, we investigated the potential for
cross resistance between chlorhexidine, colistin, AMPs and ceragenins as repeated exposure of
bacteria to chlorhexidine might result in cross resistance with colistin, AMPs or ceragenins.
Furthermore, a proteomics study on the chlorhexidine-resistant strains showed that chlorhexidine
resistance is associated with upregulation of proteins involved in the assembly of LPS for outer
membrane biogenesis and virulence factors in Pseudomonas aeruginosa.
Second, this dissertation describes the antifungal activity of ceragenins against an emerging
multidrug-resistant fungus, Candida auris. We found that lead ceragenins displayed activities
comparable to known antifungal agents against C. auris isolates. We also found that fungal cell
morphology was altered in response to ceragenin treatment, that ceragenins exhibited activity
against sessile organisms in biofilms, and that gel and cream formulations including CSA-44 and
CSA-131 resulted in a significant log reduction against established fungal infections in ex vivo
mucosal tissues.
Finally, a hydrogel film containing CSA-131 was generated on endotracheal tubes (ETTs).
ETTs provide an abiotic surface on which bacteria and fungi form biofilms that cause serious
infections. In this study, the eluting ceragenin prevented fungal and bacterial colonization of coated
ETTs for extended periods while uncoated tubes were colonized by bacteria and fungi. Coated
tubes were well tolerated in intubated pigs. The ability of ceragenins to eradicate established
biofilms make them attractive potential therapeutics for persistent infections in the lung, including
those associated with cystic fibrosis. In ex vivo studies, we initially found that this ceragenin, at
concentrations necessary to eradicate established biofilms, also causes loss of cilia function.
However, by formulating CSA-131 in poloxamer micelles, cilia damage was eliminated and
antimicrobial activity was unaffected. These findings suggest that CSA-131, formulated in
micelles, may act as a potential therapeutic for polymicrobial and biofilm-related infections in the
lung and trachea.
Keywords: antimicrobial peptides, ceragenins, CSA-131, CSA-44, antimicrobial activity,
antifungal activity, endotracheal tube, colistin-resistant bacteria, drug-resistant, Candida auris,
cilia
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Chapter 1

1.1

Introduction

The antimicrobial resistance crisis
The discovery of antibiotics was one of the most important advances in medicine. These drugs

were heralded for their effectiveness and, as a result, began to be prescribed across the world 1.
However, widespread use of antibiotics has resulted in the generation of mutational resistance in
bacteria as well as adaptational resistance mechanisms. These have led to the rise of hyper-resistant
bacteria, often called superbugs. Today, the phenomenon of antibiotic resistance has become a
global public health concern, with 700,000 global deaths annually attributed to antimicrobial
resistance (AMR). This count is expected to reach 10 million by 2050 as the decreasing
effectiveness of available market drugs continues to compound this problem 2. There are two ways
to combat this problem. First, novel antimicrobials must be researched whose mechanisms of
action are new and unique—to which superbugs are not already resistant. Second, the advancement
of AMR worldwide must be curtailed by monitoring the use of antimicrobials 3.
Currently, market conditions fail to adequately incentivize research and development of
novel antimicrobials. Newly developed drugs are used sparingly to prevent the development of
resistance in pathogens, causing novel drugs to be bought in low quantities and turn an
underwhelming profit margin 4. Without sufficient incentivization large-scale drug companies
have left for more lucrative fields. The remaining small-scale companies lack the funding
necessary to develop truly novel medicine, and often modify or improve upon existing medications,
instead. Therefore, the majority of new antimicrobials hitting the market do not operate through
an original mechanism of action and are not effective against resistant organisms. As a result, the

1

current production of novel antimicrobials is markedly insufficient for preventing the global AMR
crises 5.
To stem the threat of AMR, international efforts have already been launched to bolster the
research and development of new antimicrobials. Programs include the Joint Programming
Initiative on Antimicrobial Resistance and the Biomedical Advanced Research and Development
Authority’s Broad Spectrum Antimicrobials Program among others. While these programs are an
encouraging step in the right direction, their effectiveness has nonetheless been called into question.
For example, many of these programs focus heavily on funding early-stage research for new drugs
but lack funding for late-stage development to see these projects through to completion.
Additionally, private investment in development is poorly incentivized and the many initiatives
that have been launched are not well coordinated with each other. A possible solution to this
problem is for a global governing body such as the World Health Organization (WHO) to create a
worldwide, legally binding initiative that requires strong action to curb AMR and to incentivize
research and development of fully novel antimicrobials 6.
In this dissertation we focused on a novel class of antibiotic termed ceragenins. The previous
studies on ceragenins revealed the broad-spectrum activity of ceragenins on different organisms,
including Gram-positive and Gram-negative bacteria and fungi. The overall goal of this research
was to investigate of the efficacy of ceragenins against multi-drug resistant bacteria or fungi and
clinical application of them in medical devices.
Our studies highlighted that ceragenins retain their activity against multi-drug resistant
clinical isolates of bacteria and fungi. Moreover, application of ceragenins in endotracheal tubes
(ETTs) and cream formulation demonstrate that they have wide potential application in intubated
patients, topical infection treatment, and cystic fibrosis patients. Overall, our studies will facilitate

2

transition of ceragenins and ceragenin containing products from early clinical phases to
commercialization.

3

Chapter 2

2.1

Literature review

Introduction
Antimicrobial peptides (AMPs) are evolutionarily conserved molecules that exist in

organisms ranging from prokaryotes to humans as a first line of defense

7,8

. They are naturally

found in the skin, airways, gastrointestinal tract, and urinary and reproductive tracts with the
highest concentrations of AMPs being found in the tissues that are exposed to pathogens 9,10. They
display broad-spectrum activity against bacteria, fungi, lipid-enveloped viruses and parasites. In
higher organisms, AMPs exert additional immunomodulatory activities such as anti-inflammatory
properties, through sequestration of bacterial endotoxins, and acceleration of wound healing by
promotion of cell migration into wound beds and neovascularization. Common features of AMPs
are juxtaposed cationic amino acids and hydrophobic residues on opposing faces of helices or
sheets. This morphology provides them with a unique amphiphilic structure that selectively
associates with microbial membranes, disrupts membrane integrity, and leads to cell death.
AMPs have existed for eons and have played a central role in nearly all organisms in
controlling the growth of pathogens. Even though most common pathogens have been exposed to
AMPs for extended periods, most remain susceptible to AMPs, while pathogens have developed
high levels of resistance to most other clinically-used antibiotics

11

. The cause of the enduring

activity of AMPs may be due to a variety of factors: First, AMPs have co-evolved with the
pathogens they are fighting, and through natural selection AMPs with optimized properties are
selected for as they increase the fitness of their host. Second, while some AMPs are constitutively
expressed, some are only released or have their expression substantially up-regulated with
infection or inflammation. This non-constitutive and localized expression may also hinder a

4

pathogen’s ability to form resistance as it never is allowed to adapt to an environment that contains
sub-therapeutic levels of AMP 12. Finally, AMPs target the membranes of microorganisms rather
than specific enzymatic pathways. Consequently, resistance to AMPs requires modification to a
gross structural component of microorganisms, a process that may come with a metabolic cost or
substantial changes in interactions of the microorganisms with their environment 13.
Despite the broad-spectrum antimicrobial activities of AMPs and the belief that
microorganisms are unlikely to become resistant to AMPs, their clinical application is limited due
to the high cost of production and their degradation by bacterial proteases. In order to overcome
these clinical challenges, ceragenins were developed as non-peptide mimics of AMPs. They are
based on a common bile acid and mimic the amphiphilic morphology of AMPs with a similar
spectrum of activity against bacteria, fungi and lipid-enveloped viruses.14 Straightforward
preparation of ceragenins and their stability in the presence of proteases paves the way for largescale production and clinical application. This chapter will discuss the development of ceragenins,
their breadth of antimicrobial activities, impacts on innate immune functions and wound healing,
and specific applications of ceragenins as stand-alone antimicrobial agents and in medical
applications.

2.2

Antimicrobial peptides: source and history
The first human AMP described, lysozyme, was discovered in 1922 by Alexander Fleming

from his own nasal mucus. Further investigation demonstrated that lysozyme targets bacteria by
hydrolyzing the linkage of peptidoglycan of the cell wall in Gram-positive bacteria 15-18. However,
antimicrobial use of lysozyme was overshadowed by the discovery of penicillin in 1928, also by
Fleming

19

. The emergence of drug-resistant pathogens in the 1960s brought the potential of

5

therapeutic use of AMPs again to the attention of scientists. Pioneering work in 1956 resulted in
discovery of defensins, the first animal-originated AMPs, isolated from rabbit leukocytes 20. This
was followed by the report of lactoferrin from milk in the 1960s 21. Cecropin, first isolated from
the Cecropia silk moth Hyalophora cecropia in 1981, was the first helical AMP reported

22,23

.

Zasloff and colleagues isolated magainins from the skin of the African clawed frog Xenopus laevis
in 1987 and found that it displayed broad spectrum antimicrobial activity 24. It is also worth noting
that prokaryotes produce and release AMPs to fight other microorganisms in their environment;
however, these AMPs mostly have cyclic or branched structures. These AMPs are often
synthesized by a non-ribosomal peptide synthase through a specialized metabolic pathway, unlike
eukaryotic AMPs which are synthesized by the ribosome. To date, over 250 of these bacteriocins
have been identified from bacteria

19

. Of particular interest are the commercial antibiotics

polymyxin B (cationic) and vancomycin (non-cationic), which are isolated from Bacillus polymyxa
and Amycolatopsis orientalis, respectively. Polymyxin B displays potent antibacterial activity
against Gram-negative bacteria and vancomycin against Gram-positive bacteria 25,26.

2.3

Structure and mechanism of action of AMPs
AMPs mainly fall into three classes: α-helical, β-sheet, and extended, depending on their

secondary structures

27,28

. Magainins and the human cathelicidin LL37 (hereafter LL-37) are

prominent examples of AMPs with substantial α-helical structure

29,30

. β-sheet AMPs include

defensins and feature disulfide bond that stabilize their structure 31. AMPs derived predominantly
from one type of amino acid are categorized as extended AMPs and include human histatins, which
are rich in histidine, and bovine indolicidin, which is rich in tryptophan and arginine 32.
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Nearly all AMPs are amphipathic, meaning they have both cationic and hydrophobic character.
However, unlike typical surfactants, with polar head groups and hydrophobic tails, AMPs display
polar, cationic functionality on one face of the molecule with hydrophobic groups juxtaposed on
the opposite face 33. Defensins and cathelicidins constitute the major families of membrane-active
AMPs in vertebrates 34. With these AMPs, an initial, selective electrostatic interaction between the
positive charges on one face of the AMPs and negative charges of membranes occurs. Due to their
facial amphiphilicity, the hydrophobic domains of AMPs cannot stably insert into intact
membranes, and at sufficient local concentrations, AMPs cause membrane perturbation leading to
a loss of polarization, resulting in cell death. Membrane composition allowing selective association
of AMPs with microbial membranes plays a key role in cell selectivity 35. For example, magainins
show higher affinity for anionic phospholipids, which are highly represented in bacterial
membranes. Cell membranes of higher organisms, however, feature neutral phospholipids and
cholesterol, which diminish AMP interactions 36,37. For this reason, much higher concentrations of
AMPs are required to kill cells from higher organisms as compared to microbial cells. Targeting
of the cell membranes by AMPs gives rise to their breadth of spectrum of activity: bactericidal
activity against Gram-negative and positive bacteria, antifungal activity and even activity against
lipid-enveloped viruses. This breadth of activity may offer advantages over antibiotics that target
specific cellular processes, such as DNA and protein synthesis, leading to narrow spectra of
activity. Membrane-targeting properties of AMPs contribute to the rapid antimicrobial activity,
with some AMPs able to kill microorganisms with only seconds of exposure 23,38.
In higher eukaryotic organisms, AMPs display immunomodulatory activities

39

, including

anti-inflammatory properties through the sequestration of bacterial endotoxins such as
lipopolysaccharide (LPS). In addition, multiple studies support the idea that human AMPs improve

7

wound healing via promotion of cell migration into wound beds, clearance of bacteria from the
wound bed, reduction of local inflammation and facilitation of wound restructuring through
angiogenesis, and neovascularization 40,41.
AMPs are generally constitutively expressed in healthy epithelium, and their production is
upregulated in response to injury or infection to moderate microbial proliferation and signal host
cells to activate secondary immunomodulatory roles 42. For example, a study with a human skin
wound healing model, LL-37 was expressed acutely post-injury, whereas its concentration was
reduced in chronic ulcer epithelium where re-epithelization is impaired, suggesting that LL-37
plays a prominent role in wound closure 43.
Despite the broad-spectrum antimicrobial activities of AMPs and their wound-healing and
immunomodulatory properties, there are factors that limit their clinical applications. These include
their susceptibility to proteases released by bacteria, the high cost of producing them on a large
scale, decreased activity when immobilized, and folding problems in the production of some large
AMPs 23.
We developed ceragenins as non-peptide mimics of AMPs

44

. They are synthesized from

cholic acid, a common bile acid, in few synthetic steps (Figure 2-1) 45-47. Due to the fact that they
are not peptide-based, they are not substrates for ubiquitous proteases. Preparation and purification
of ceragenins on a large scale is relatively straightforward, they are stable under physiological
conditions and even long-term storage in solution does not reduce their antibiotic activities14,48. As
ceragenins follow the amphiphilic structure of AMPs they display a similar spectrum of activity
against bacterial, fungi and lipid-enveloped viruses 49.
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Figure 2-1: Structures of selected ceragenins CSA-13, CSA-131, CSA-142, CSA-44 and CSA-144

2.4

Design of ceragenins
Preliminary design of the ceragenins (examples in Figure 2-1) was based on the presumed

lipid A binding domain of polymyxin B. The primary amines from diaminobutyric acid groups in
polymyxin B are oriented on one face of the molecule, and to mimic this arrangement, three
primary amines were tethered to cholic acid to generate similar amine spacing in ceragenins.
Tether lengths were incrementally varied to determine the optimal spacing between the steroid
backbone and the amine groups 50-53. These initial attempts to mimic the structure of polymyxin B
resulted in preparation of ceragenins with activity against Escherichia coli [minimal inhibitory
concentration (MIC) range 2.0–46 μg mL−1]. A truncated form of polymyxin B, polymyxin B
nonapeptide, permeabilizes the outer membranes of Gram-negative bacteria, sensitizing them to
hydrophobic antibiotics. With the initial series of ceragenins, this type of sensitization was
observed with erythromycin against E. coli; concentrations of CSA-8 as low as 1 μg mL−1 lowered
the MIC of erythromycin from 70 to 1 μg mL−1 54. Further structure-activity studies demonstrated
that the chain extending from the D ring of the bile acid played a central role in controlling direct
antibacterial activity vs. sensitizing activity of Gram-negative bacteria. With lipophilic groups
attached to this chain, the resulting ceragenins displayed broad-spectrum antibacterial activity

9

(Gram-negative and -positive). For example, CSA-13 gave an MIC of 3.0 μg mL−1 against E. coli
(Gram-negative) and 0.40 μg mL−1 against Staphylococcus aureus (Gram-positive). Ceragenins
lacking lipophilic groups on the D-ring retained antibacterial activity against Gram-positive
bacteria but lost substantial activity against Gram-negative bacteria. For example, CSA-8, without
an extensive lipid chain, gave an MIC of 36 μg/mL against E. coli, and an MIC of 2.0 μg/mL
against S. aureus. Nevertheless, ceragenins lacking lipophilic groups extending from the D ring
retained the ability to sensitize Gram-negative bacteria to hydrophobic antibiotics 55.
From these results, we postulated that lipid chains extending from the D ring enabled
ceragenins to traverse the outer membrane and exert antibacterial activity through interactions with
the cytoplasmic membrane. Gram-positive bacteria lack an outer membrane, and they are
susceptible to ceragenins with and without a lipid chain. Ceragenins lacking a lipid chain extending
from the D ring remain on the outer surface of the outer membrane, and association of these
ceragenins with the lipid A component of the membrane causes perturbations in the membrane
that allow hydrophobic antibiotics to traverse the membrane 47,50,56.
Further structure activity studies involved replacement of the ether bonds tethering the amines
to the bile acid with amide and ester groups. To use amide groups in the tethers, it was necessary
to synthesize a tri-amino version of cholic acid 57. These amines were functionalized with amino
acids, generating amides. The resulting ceragenins displayed antibacterial activity, but less than
that of the ceragenins with ether bonds for the tethers. By differentially protecting the three amines
in the tri-amino version of cholic acid, it was possible to sequentially incorporate different amino
acids at each amine. Although this method of preparing ceragenins resulted in the production of
large numbers of compounds, none were as active as ether-based compounds. The ester-based
compounds (e.g., CSA-44) were prepared from cholic acid, and some of the resulting compounds
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showed activity that rivaled that of the ether-based compounds. A feature of the ester-based
compounds is that the ester groups spontaneously hydrolyzed in water (half-life of 37 days at pH
7). Hydrolysis of all of the esters gave cholic acid, an amino acid and a waxy alcohol 58-60.

2.5

Mechanism of action of ceragenins
A primary mode of antimicrobial activity of AMPs involves selective association with

microbial membranes, and this association is mediated by ion pairing of positively charged AMPs
with negatively charged microbial membranes 61. Similarly, ceragenins selectively associate with
negatively charged components of bacterial cell membranes, and ceragenins have been shown to
sequester bacterial endotoxins (e.g., LPS and lipoteichoic acid), which make up membranes of
Gram-negative and positive bacteria

62,63

. This affinity for bacterial membrane components

translates into cell selectivity; in studies with intact cells, ceragenins were shown to selectively
associate with prokaryotes over mammalian cells, and this selective affinity is likely due to the
higher net negative charge present on prokaryotic membranes 35.
As a consequence of the interactions of AMPs with the outer membranes of Gram-negative
bacteria, blebs form on the surface 64-66, and similar morphological changes occur with ceragenintreated, Gram-negative bacteria

56

. This observation, along with measurement of affinity of

ceragenins for the lipid A portion of lysophosphatidic acid (LPA) and the cell selectivity described
above, attest to the interactions between ceragenins and the outer membranes of Gram-negative
bacteria. However, perturbation of the outer membrane is insufficient for cell death, and the
ultimate target must be the cytoplasmic membrane

67,68

. As described above, a lipid chain

extending from C24 is required for ceragenins to traverse the outer membrane of Gram-negative
bacteria and gain access to the cytoplasmic membrane. A ML-35p mutant strain of E. coli was
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used to show that ceragenins containing such a lipid chain traverse the outer membranes of Gramnegative bacteria and to gain access to the cytoplasmic membrane 69. Association of ceragenins
with the cytoplasmic membranes of bacteria, in sufficient concentrations, leads to formation of
transient membrane defects, membrane depolarization and cell death. This mechanism of action is
best described by the carpet model proposed for the activity of AMPs with bacteria 35. Although
antiviral and antifungal mechanisms of action of ceragenins are not completely understood,
electron micrographs of ceragenin-treated vaccinia virus exhibited considerable morphological
changes in the viral lipid envelope, and ceragenin-treated fungal cells displayed changes in cell
shape, similar to that observed with AMPs 70.

2.6

Antimicrobial spectrum of activity of ceragenins

2.6.1

Antibacterial activity

The antimicrobial activities of ceragenins have been studied more with bacteria than with
other organisms (e.g., fungi and viruses). While they display activity against both Gram-positive
and Gram-negative bacteria, ceragenins tend to be active at lower concentrations against Grampositive bacteria, possibly due to the permeability barrier of the outer membranes of Gramnegative bacteria. Ceragenins have shown activity against a wide array of clinical isolates and
drug-resistant bacteria, supporting their potential for clinical use as the threat of antibiotic-resistant
bacteria grows55,71,72. To highlight the broad-spectrum antibacterial activities of ceragenins, their
abilities to eliminate drug-resistant organisms are highlighted below.
Susceptibility experiments of CSA-13 with four clinical isolates of vancomycin-resistant S.
aureus and 50 clinical isolates of glycopeptide-intermediate and heterogeneous glycopeptide-
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intermediate S. aureus showed that the MIC50, MIC90 and MBC of all isolates was 1 μg mL−1

73

.

These results demonstrate that there is no cross reactivity between glycopeptides and ceragenins.
A more pressing concern may be with multi-drug resistant Gram-negative pathogens. In a study
with 60 carbapenem-resistant Acinetobacter baumannii strains isolated from blood specimens of
bacteremia patients, CSA-13 gave MIC50 and MIC90 of 2 and 8 μg mL−1, respectively. Similar
results were observed with 50 strains of Pseudomonas aeruginosa isolated from cystic fibrosis
patients 74.
Ceragenins have also shown activity against cariogenic and periodontopathic bacteria48.
Susceptibilities of broad-spectrum pathogens associated with oral and upper respiratory tract
infections including Streptococcus mutans (the leading etiological agent of dental caries) and S.
aureus (which often colonizes the nasopharynx) were determined with ceragenins CSA-13, CSA90 and CSA-92 and compared to LL-37. As shown in Table 2-1, all tested ceragenins revealed
significantly potent antibacterial activity when compared to LL-37 75. Interestingly, Lactobacillus
casei, considered a beneficial member of the gut microfluora, was much less susceptible to
ceragenins and LL-37 than other organisms, indicating a possible adaptation of this strain to
become tolerate to LL-37 and probably ceragenins.
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Table 2-1: MIC [MBC] µg/mL of LL-37, CSA-13, CSA-90, CSA-92 against tested strains
associated with oral infections.

The permeability barrier of the outer membranes of Gram-negative bacteria and the action of
efflux pumps in these membranes contribute to resistance profiles of bacteria 76. Association of
ceragenins with the outer membranes decreases the permeability barrier resulting in synergy
between ceragenins and other antibiotics 77. For example, synergistic activities of CSA-13 were
reported with colistin, tobramycin, and ciprofloxacin against P. aeruginosa strains isolated from
cystic fibrosis patients. The synergistic effect of CSA-13 was stronger with colistin (54 % of tested
strains) compared to tobramycin (25 % of tested strains) 78. Further investigation showed that CSA13 also displays synergistic activity with cefepime or ciprofloxacin against clinical isolates of P.
aeruginosa, including multidrug-resistant P. aeruginosa

79

. In related studies, the synergistic

effects of ceragenins with AMPs were studied; combinations of CSA-13 with selected AMPs LL37, lysozyme, lactoferin, or secretory phospholipase A were evaluated against bacteria causing
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topical infections. As expected, CSA-13 exhibited more potent antibacterial activity in the
presence of all tested AMPs 80.

2.6.2

Antifungal activity

The continued emergence of drug-resistant fungal pathogens has highlighted the urgent need
for novel antifungal agents 81. AMPs display antifungal activity 23 and this observation led to the
question of whether ceragenins, as mimics of AMPs, would also display antifungal activity.
Fungicidal activity of ceragenins CSA-13, CSA-131 and CSA-192 was evaluated against four
fluconazole–resistant Candida strains 82. Interestingly, these ceragenins showed higher antifungal
activity against these strains than LL-37 and omiganan, a synthetic AMP designed for antifungal
activity. In addition to Candida spp., CSA-131 and CSA-192 were also found to be active against
a broad array of fungal strains including Cryptococcus, Aspergillus, Scedosporium, Rhizopus and
Blastomyces.
The primary antifungal mechanism of action of AMPs is proposed to involve interactions and
potentially disruption of the fungal membrane. Apoptosis as a result of increased reactive oxygen
species (ROS) and decreased mitochondrial function have been also observed

83-86

. In a recent

study, LL-37 or CSA-13 immobilized on magnetic nanoparticles were to shown to increase ROS
generation in fungal cells, suggesting an additional pathway of antifungal activity with Candida
spp. (Figure 2-2) 87. Nevertheless, additional information is still required to fully understand how
ceragenins target and kill fungal cells.
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Figure 2-2: Proposed mechanism of positively charged coated magnetic 398 nanoparticles with LL-37 or CSA-13 against fungal
cells membrane and contribution of LL-37/CSA-13 to generation of ROS.

2.6.3

Antibiofilm activity

Bacteria and fungi naturally exist in planktonic and biofilm forms. Planktonic cells are single,
free-growing microorganisms, while biofilms form from groups of cells that aggregate through a
protective extracellular polymeric matrix

88

. Biofilms are now thought to be involved in most

infections, including chronic wounds, medical device-related infections, and cystic fibrosisassociated pneumonia. Eradication of biofilms can be a particularly daunting task due to the
protective environment provided by the extracellular matrix and because cells within the biofilm
are slow-growing and have low metabolic activity and therefore do not respond to antibiotics that
target and inhibit cells that are rapidly growing and reproducing 89. These factors lead to a 100–
1,000-fold increase in the ability of the bacteria or fungi to resist antibiotic treatment, compared to
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planktonic cells

23

. For example, β-lactam antibiotics inhibit the synthesis of the peptidoglycan

layer of the bacterial cell wall and while their effect is considered bactericidal, it is most effective
against cells that are growing and preparing to divide, as they require more peptidoglycan

90

.

Consequently, β-lactams lose activity as bacteria transition from planktonic to sessile forms found
in biofilms. Ceragenins and AMPs, on the other hand, target the bacterial membrane, and are able
to kill bacterial and fungal cells regardless of whether they are rapidly growing, dividing, or sessile
42

. In addition, the relatively small size of ceragenins allows them to penetrate the extracellular

matrix of biofilms and gain access to the cells within 14. A comparative study of ceragenins with
ciprofloxacin indicated that a much lower concentration of CSA-13 was required to eradicate an
established biofilm consisting of a meticillin-resistant strain of S. aureus in comparison with
ciprofloxacin. While treatment with CSA-13 caused a complete eradication of biofilm at a
concentration between 16 and 32 μg mL−1, treatment with ciprofloxacin resulted in an insignificant
reduction of biofilm even at a concentration of 64 μg mL−1 91. In a similar study, it was observed
that CSA-13 inhibits biofilm formation of both mucoid and nonmucoid phenotypes of P.
aeruginosa at 1 μg mL−1 92. It was also noted that the rhlAB operon, which is controlled by quorum
sensing and regulates rhamnolipid synthesis, was not an intracellular target of CSA-13 involved
in the inhibition of biofilm formation. Further study with confocal laser scanning images of
biofilms formed by P. aeruginosa revealed that bactericidal penetration of ceragenins into the
biofilm matrix occurs within only 30 minutes of exposure of the ceragenin to the established
biofilm 93.

2.6.4

Sporicidal activity

Some genera of bacteria such as Bacillus and Clostridium undergo a process of sporulation in
response to unfavorable environmental conditions including depletion of nutrients 94. Sporulation
17

enables bacteria to form inert, dormant spores, and this process involves formation of a
multilayered structure different than vegetative cells

95

. Given the membrane-permeabilizing

properties of ceragenins, activity of CSA-13 against the vegetative and spore forms of B. subtilis
was assessed 96. Treatment with CSA-13 significantly diminished the viability of vegetative cells
and inhibited spore germination. Moreover, the surface electrical features of spores and vegetative
cells measured through zeta potential provided evidence that the surfaces of spores exhibit a larger
negative charge than vegetative cells. It was postulated that this charge density was the cause of
the high affinity of CSA-13 for spore surfaces. Raman spectroscopy analysis further illustrated
that ceragenin-treated spores release more calcium dipicolinic acid than untreated cells, implying
that there is an increased permeability in the barriers of these spores, which increases their
susceptibility to ceragenins.

2.6.5

Antiviral activity

AMPs exhibit antiviral activity through several mechanisms. First, by targeting the viral
envelopes of lipid-enveloped viruses and disrupting membrane integrity, AMPs cause viruses to
lose the ability to infect the host cells. Second, AMPs block viral receptors on the cell surface and
prevent viruses from binding to host cells 23. This can be seen in the interaction between θ defensins
and viral glycoproteins of the Herpes simplex virus

97

. The antiviral activity of LL-37 against

vaccinia virus has been established, and subsequently the antiviral activity of CSA-13 was studied
against the same virus, which is a large double-stranded DNA virus that can infect a wide variety
of mammalian cells as well as invertebrate cells

70

. CSA-13 showed potent antiviral activity

through targeting the viral envelope. Additionally, topical application of CSA-13 in a murine
model of vaccinia infection showed a substantial reduction in the number of satellite lesions that
formed and in viral replication in the epidermis of infected mice.
18

2.6.6

Anti-parasite activity

The actions of a few AMPs have been studied with parasites, and anti-parasitic activities have
been attributed to direct interactions with cell membranes. Magainins were reported as the first
AMPs with anti-parasitic properties, displaying activity against Paramecium caudatum

24

.

Cathelicidin is another example of an anti-parasite AMP, with activity against Caernohabditis
elegans through pore formation on the cell membrane 98. CSA-13 was also tested for anti-parasitic
activity and showed an LD50 of ca. 9 and 5 μM with Trypanosoma cruzi and Leishmania major,
respectively

99

. Acanthamoeba castellanii is a causative agent of corneal infections known as

acanthamoeba keratitis. The parasite has two phases of life cycle, including cysts (the most
resistant form) and trophozoites (the replicating stage)

100

. An in vitro evaluation of CSA-13 at

concentrations of 25, 50, 75, and 100 mg mL−1 against both cyst and trophozoite forms of A.
castellanii showed that CSA-13 inhibited trophozoite growth in a dose- and time-dependent
manner. For example, within one hour of exposure to 100 mg mL−1 CSA-13, no viable trophozoites
were detected 101. Further study was performed using ceragenins CSA-13, CSA-44, CSA-131, and
CSA-138 against metronidazole-susceptible and metronidazole-resistant strains of Trichomonas
vaginalis, a parasitic protozoan transmitted via sexual intercourse and hosted only in humans.
Overall, all tested ceragenins killed the tested T. vaginalis with a similar activity against
metronidazole-susceptible and resistant strains, and CSA-13 was the most effective ceragenin in
this study 102.

2.7

Effect of mucins, DNA and F-actin on the antimicrobial activities of ceragenins
The antimicrobial activities of AMPs and ceragenins may be influenced not only by

modifications made by bacteria but also by production of specific molecules produced by the host.
Because mucins, DNA and F-actin have been shown to deactivate AMPs, the question arose of
19

how these compounds would impact the activities of ceragenins. Comparative studies showed that
these molecules had much less impact on the antibacterial activities of ceragenin CSA-13 than
AMPs 63,103. This observation is particularly important for potential applications of ceragenins in
treating infections associated with cystic fibrosis. Mucins, DNA and F-actin are produced at
relatively high concentrations in the lungs of those with cystic fibrosis. The smaller size of CSA13 and lower positive charge, relative to endogenous AMPs, were proposed to be why the
antibacterial activity of CSA-13 is less compromised by mucins, DNA and F-actin than AMPs. In
a following study, the effects of selected depolymerizing factors (plasma gelsolin, DNase 1, and
poly-asparate) on polyelectrolyte networks of F-actin and DNA in purulent body fluids were
assessed in order to determine if they would improve the bactericidal activities of CSA-13, LL-37,
tobramycin, colistin and polymyxin

104

. The depolymerizing compounds were found to enhance

the activities of the tested antimicrobials, particularly CSA-13 and LL-37. Stronger antibacterial
activity was observed with combination of DNase 1 and poly-aspartate as compared to the
individual depolymerizing compounds

104

. These results provide strong evidence that because

ceragenins possess potent antibacterial activity that is even sustained in the presence of complex
anionic compounds, they offer excellent potential in treating chronic lung infections in cystic
fibrosis patients, where the accumulation of polyanions creates major treatment obstacles.

2.8

Effect of poloxamer micelles on the antimicrobial activities and cytotoxicity of ceragenins
Clinical use of AMPs and ceragenins requires selective toxicity for microorganisms over host

cells. One measure of cytotoxicity used to evaluate membrane-active compounds is measurement
of concentrations of investigational antimicrobials that cause hemolytic activity. One such study
showed that CSA-13 is not hemolytic at concentrations required for bactericidal activity and
hemolysis was first observed at concentrations 10 times the bactericidal concentration 63. Further
20

evaluation of hemoglobin release from human red blood cells showed that CSA-13 at a
concentration of 10 mg mL−1 causes lysis in less than 10 % of erythrocytes while total hemolysis
occurs at a concentration of 50 mg mL−1

105

. These concentrations are higher than the

concentrations required for bactericidal activity of ceragenins. In studies with HaCat cells, the
toxicity profile of CSA-13 was similar to that of LL-37, without any toxicity at bactericidal
concentrations 75.
Cytotoxicity was explored in a comparative study of ceragenins with bacterial cells and human
umbilical vein endothelial cells. It was found that CSA-13 permeabilizes the plasma membrane of
these eukaryotic cells in addition to the bacteria cells 106. In an attempt to attenuate this effect of
CSA-13 on eukaryotic cells, it was combined with the poloxamer Pluronic® F-127, a nonionic
surfactant comprised of polyoxyethylene–polyoxypropylene copolymers (hereafter referred to as
pluronic). The low toxicity of this poloxamer, great solubilizing capacity, and unique
thermoreversible and drug releasing properties contribute to its applications in drug delivery as a
pharmaceutical vehicle

107

. This poloxamer forms micelles that associate with hydrophobic and

amphiphilic compounds. Formulation of ceragenins with pluronic resulted in well-defined
micelles with lower toxicity toward eukaryotic cells, while antibacterial activity was not
substantially impaired 80,108.

2.9

Nanoparticles as carriers of ceragenins
Metal-based nanoparticles provide a unique platform for the presentation of ceragenins in a

pre-aggregated form. In addition, the distribution of magnetic nanoparticles can be controlled in
tissues and silver-based nanoparticles display inherent antimicrobial activity. Multiple methods
have proven effective in attaching ceragenins to nanoparticles. One method uses CSA-124, a
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ceragenin formulated with a thiol group appendage. The thiol group can coordinate with thiophilic
metals, such as silver, producing a monolayer on the surface of the nanoparticles

109

. Another

method requires the generation of an aldehyde-containing surface on the nanoparticles. Ceragenins
contain multiple amine groups, and these groups reversibly form Schiff bases with the aldehydes.
On a surface with high aldehyde density, nanoparticles can then aggregate ceragenins in high
concentrations 110.
Hoppens et al.

109

coated silver nanoparticles with CSA-124 and found that they were five

times more bactericidal than silver alone. These nanoparticles displayed MICs of ca. 12 and 24
ppm against S. aureus and E. coli, respectively. Niemirowicz et al.

110

showed that magnetic

nanoparticles coated with ceragenins retained their bactericidal activity. This association also
increased the biocompatibility of ceragenins. Further testing also showed that even without direct
conjugation of ceragenin to the nanoparticle, synergistic activity between nanoparticles and
ceragenins occurred 111.
Durnás et al.

112

also evaluated magnetic nanoparticles for their activity against selected

anaerobic bacteria often implicated in human disease. In vitro models testing CSA-13 and CSA131 attached to nanoparticles showed comparable or stronger bactericidal activity against all of
the tested strains, which included Bacteroides fragilis, Propionibacterium acnes, and a clinical
isolate of Clostridium difficile (Table 2-2). Nanoprticles including CSA-131 also showed enhanced
ability in preventing biofilm formation of Bacteroides fragilis and Propionibacterium acnes.
Neimirowicz et al.

87

further studied the candidacidal activity of magnetic nanoparticles coated

with CSA-13 and CSA-131. Their experiments confirmed that ceragenins attached to nanoparticles
retained their highly potent fungicidal activity against multiple laboratory and clinical species of
C. albicans, C. glabrata, and C. tropicalis.
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Table 2-2: MIC [MBC] µg/mL of LL-37, CSA-13 and CSA-131 functionalized on nanoparticles against
tested anaerobic strain.

2.10 Medical applications of ceragenins

2.10.1 Contact lenses
Contact lenses are abiotic surfaces on which pathogens can form biofilms and proliferate,
potentially leading to microbial keratitis, a serious condition that affects up to 25,000 Americans
each year. AMPs are present in conjunctival fluid and provide the surface of the eye an innate
immune function that controls bacterial growth. Efforts have been made to provide contact lenses
with a comparable innate immune function by attaching AMPs to lenses, and this combination
reduced the ability of bacteria to colonize lenses

113

. However, the relatively high cost of AMPs

and concerns over thermal stability (lenses are generally autoclaved in the final stages of
production) complicate the use of AMPs in contact lenses. The relatively low cost of ceragenins
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and the thermal stability of the ether-based compounds make them attractive alternatives to AMPs
in providing an innate immune defense to contact lenses. In addition, ceragenins contain no
chromophores (colorless), they are soluble in the polymers used to make lenses and they do not
interfere with the polymerization processes involved in lens formation 114.
Two approaches were used in combining ceragenins and contact lenses. The first required
appending a ceragenin with an acrylamide group, generating CSA-120 and allowing the ceragenin
to participate in the radical polymerization steps that form lenses. The second involved formation
of lenses in the presence of ceragenins, and in this approach ceragenins were able to elute from
lenses.
Photo-initiated polymerization of acrylate groups is used to form hydrogel contact lenses.
Acrylamide groups can participate in the polymerization process, and addition of CSA-120 to the
reaction allowed covalent attachment of the ceragenin to the lens hydrogel. Up to 1.25 % CSA120, relative to the dry mass of a lens, could be incorporated without causing phase separation in
the hydrogel. When incorporated at this concentration in lenses, biofilm formation (S. aureus) was
reduced by 3 logs after 24 h when tested in a 10 % bacterial growth medium. When 100 % medium
was used, however, this inhibitory effect was lost, likely because the permanently bound ceragenin
was covered by bacteria and bacterial debris.
To improve the duration of activity of ceragenins in contact lenses, a series of ceragenins were
prepared in which the lengths of the lipid chain extending from bile acid were incrementally varied.
The intent of these experiments was to match the hydrophobicity of the ceragenin to the
hydrophobic domains in the lens hydrogel to limit elution of the ceragenin from the lens. With a
shorter lipid chain, the ceragenin eluted too rapidly; however, with CSA-138, elution extended
over weeks and provided antibacterial activity. At 1 % of the weight of dry lenses, CSA-138
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inhibited the colonization of lenses by S. aureus for up to 30 days and by P. aeruginosa for up to
15 days (Figure 2-3) with daily inoculation with bacteria in fresh media. These results demonstrate
that by tuning the properties of ceragenins to a hydrogel, the elution profile of the ceragenin can
be controlled to provide long-lasting antimicrobial activity 114.

Figure 2-3: Bacterial population in nutrient media after 24 h incubation. Inoculated with P. aeruginosa ATCC
27853 (A), inoculated with S. aureus IBG 031 (B). Control lenses do not include any ceragenins. Lenses contained
1 % of selected ceragenins, relative to the dry weight of the lens. Every 24 h lenses were placed in fresh media and
reinoculated.
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2.10.2 Implanted medical device coatings
Implant-related infections affect thousands of patients each year

115

, and active-release

antimicrobial coatings have been designed in order to combat this issue. These coatings release
antimicrobial agents into the surrounding tissue and fluids with the intent of preventing biofilm
formation on the device and infection at the implant site 116,117. However, due to the presence of
sessile organisms, if a biofilm forms on a device or the device is implanted in the presence of an
established biofilm, most conventional antibiotics cannot fully protect implanted devices. An
active-release coating containing ceragenins is an attractive option because ceragenins exhibit
antibacterial activity against established biofilms, they do not lose effect in the presence of
proteases and other enzymes, and they are easily incorporated into stable polymer coatings.
An active-release coating containing CSA-13 was first developed and described by Williams
et al.

118

on fracture fixation plates. Investigation of the polymerization of a silicone coating

showed that the incorporation of CSA-13 in particulate form (18 % w/w) had no impact on the
physical properties of the coating and SEM observation revealed that the CSA-13 was distributed
evenly throughout the coating. Of critical importance, when placed in aqueous solution, CSA-13
eluted from the coating over a span of 30 days. Furthermore, thermal stability testing of the coating
demonstrated that coated fixation plates retained stability at elevated temperatures, providing
further evidence that the CSA-13-silicone combination would be a viable option for the coating of
implanted devices 116,119. In order to evaluate this coating in vivo, biofilms of methicillin-resistant
S. aureus (MRSA) were grown on a polymer mesh. After being allowed to reach population
densities of over 109 CFU cm−2, the mesh was implanted on the tibia of sheep and then immediately
covered with a fracture fixation plate that was coated with CSA-13-silicone. Following inoculation,
each sheep in the control group developed infection, while those that received fixation plates
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coated with CSA-13 were fully protected from developing infection over the course of the 12week study. Investigation of the surrounding tissue showed that the coating was well tolerated,
with no evidence of cytotoxicity or inhibition of wound healing. Remarkably, it was noted that
there was an increase in bone healing in the presence of ceragenin.
The ability of this coating to prevent infection caused by planktonic bacteria was also
evaluated in vitro and in vivo 120. The coating was applied to porous titanium plug implants and
placed in mouse models infected with MRSA. While control mice had to be euthanized per
protocol shortly after the start of the experiment due to effects of infection, mice with CSA-13
coated implants were protected from infection for the duration of the 12-week study. Furthermore,
CSA-13 released from implants did not damage skeletal attachment sites of the titanium plug
implant compared to controls. Taken together, these in vivo studies provide evidence that
ceragenin-containing coatings can provide an effective antimicrobial function to implanted devices,
allowing for the eradication of both planktonic and biofilm-associated bacteria.

2.10.3 Bone fractures
Aside from their antimicrobial properties, AMPs have been shown to influence bone healing
121

. Considering this observation, the abilities of ceragenins to impact bone growth were

determined. Selected ceragenins were tested in a rat femur-based model of bone regrowth to
determine whether they would accelerate bone regrowth when used alone or in combination with
bone morphogenic protein-2 (BMP-2), which is used clinically to accelerate bone regrowth. Of the
ceragenins that were tested, CSA-90 displayed the most potent activity 122. To determine if CSA90 could positively impact bone regrowth while providing antibacterial protection of bone injury,
a model of bone regrowth, complicated with infection, was used in a similar rat femur-based study.
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As anticipated, CSA-90 functioned to both prevent infection and potentiate the activity of BMP-2
in repairing and regrowing bone. In contrast, untreated rats had to be sacrificed per protocol within
two weeks of fracture due to declining health. Because open fractures are very often complicated
by infection, most often due to pathogens that dwell on the skin including S. aureus, the ability of
ceragenins to both aid in bone regrowth while also serving to prevent infection at the fracture site
could provide profound benefit to patients.

2.10.4 Imaging infections
AMPs and ceragenins display affinity toward bacterial membranes, and efforts have been
made to leverage this property into selective association of AMPs or ceragenins, labeled with
imaging agents, for use in imaging bacterial infections

123,124

. As further evidence of the affinity

of ceragenins for bacterial membranes, CSA-124 was covalently attached to nanoparticles
consisting of a silver shell with a maghemite core
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. Imaging of the nanoparticles confirmed

selective association with intact bacteria, with particular affinity for S. aureus. In vitro MRI studies
further verified that these nanoparticles were able to adhere to S. aureus, indicating their potential
to be used as contrast agents for use in imaging deep tissue infections 125.
Technicium (99mTc)-labeling of CSA-13 was also investigated as a means of imaging
infections in mice. CSA-13 was chosen specifically because its multiple amine groups allow it to
form stable complexes with the metal ion. Following direct infection of the thigh muscle in mice
with S. aureus, the CSA-13-99mTc complex was administered. Imaging showed that the complex
accumulated at the infection site and also in the kidneys 126. Further efforts were made to alter the
binding between the ceragenin and the technicium in order to allow the amine groups to remain
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free and available to form ionic interactions with bacterial membranes 127. This modified complex
has been shown to associate with S. aureus in in vitro studies.

2.10.5 Gastrointestinal diseases
Helicobacter pylori is carried by about half of the world’s adult population. While carriers are
often asymptomatic, infection can lead to severe ulceration and gastritis, and is associated with
gastric adenocarcinoma. The emerging threat of antibiotic-resistant strains led Leszczynska et al.
128

to test whether ceragenins could be used as a viable treatment option. They found that CSA-13

displayed significantly lower minimum bactericidal concentrations (MBC) against a variety of H.
pylori clinical isolates as compared to LL-37. Furthermore, under simulated gastric conditions in
the presence of low pH and pepsin, CSA-13 retained its bactericidal activity while the activity of
LL-37 was lost. Interestingly, H. pylori, with its unique defense mechanisms of incorporating host
cholesterol into it membrane and activity through its HefC efflux pump, showed some resistance
to ceragenins, which was based on the presence of cholesterol in the bacterial membrane 129.
The impact of CSA-13 in gastrointestinal infections caused by Clostridium difficile has been
studied in a mouse model 130. Oral administration of an active formulation of CSA-13 containing
Eudragit and methylcellulose resulted in CSA-13 release in the terminal ileum and colon where
the environmental pH is alkaline. The inhibition of C. difficile spore germination and cell viability
by CSA-13 was measured at 4 μg mL−1. Both subcutaneous and oral administration of CSA-13
decreased

the

concentration

of

C.

difficile

in

fecal

samples

of

mice,

however

Peptostreptococcaceae bacteria abundance increased suggesting that CSA-13 suppresses C.
difficile via modulation of intestinal microbiota. Therefore, other microbial species and the balance
of the gut microbiota should be considered with regard to further therapeutic application of CSA-
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13 in gastrointestinal diseases. According to the observations from this study, the protective action
of CSA-13 could be generated through the direct suppression of C. difficile, by lowering the levels
of pro-inflammatory metabolites (endocannabinoids), or by increasing the levels of protective
metabolites (citrulline, 3 aminoisobutyric acid, retinol, and ursodeoxycholic acid) in the intestine
130

.

2.11 Conclusions
The central and critical roles that AMPs play in innate immunity have been well documented
and include broad-spectrum antimicrobial activities, the ability to sequester microbial endotoxins
and thereby inhibit inflammatory processes and additional activities that accelerate wound healing.
Recognition of these roles has led to intense research of AMPs; for example, thousands of papers
have been published describing activities of the human cathelicidin LL-37. The potential for
therapeutic use of AMPs has also been well recognized; however, issues related to clinical use
have also emerged: “AMPs possess some limitations that hamper their clinical and commercial
development such as high production costs, potential toxicity, susceptibility to proteases (also in
the wound fluid), and unknown pharmacokinetics”

131

. By abandoning peptide structure, while

retaining overall morphology, ceragenins provide a means of reproducing the beneficial properties
of AMPs without incurring many of the issues hampering clinical use of AMPs.
Current studies with ceragenins have focused on applications in tissues that express relatively
high amounts of AMPs, and ceragenins have proven to be well tolerated in these tissues. However,
less work has been done with potential systemic exposure to ceragenins. Use of ceragenins in
coatings of medical devices and at bone fractures could lead to wider exposure, but no adverse
events have been observed. Intraperitoneal injection of CSA-13 into mice in an infection model
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showed efficacy without measured toxicity 132. The possibility of systemic use of ceragenins exists,
but the membrane-targeting activity of ceragenins argues that their most attractive uses will be in
localized applications. With successful demonstration of efficacy in vitro in multiple animal
models, it is anticipated that ceragenins will continue development toward clinical use and
eventual applications in replacing or augmenting the activities of endogenous AMPs.
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Chapter 3

Susceptibility of colistin-resistant, Gram-negative bacteria to antimicrobial

peptides and ceragenins

3.1

Introduction
The continuous emergence of drug-resistant bacteria has led to dire predictions about a

possible “post-antibiotic” era in which common infections will not be treatable with our current
arsenal of antibiotics

133,134

. Of particular concern are Gram-negative bacteria because these

organisms are inherently resistant to many antibiotics due to the permeability barrier provided by
their outer membranes and the efflux pumps located therein 17,60. To treat infections from Gramnegative infections, clinicians are increasingly using colistin, a member of the polymyxin family
of antibiotics

135

. Colistin is considered the antibiotic of “last resort” because, while it has side

effects including nephrotoxicity and ototoxicity, it is broadly active against Gram-negative
bacteria 136-138. Isolation of colistin-resistant bacteria in many countries underscores the need for
development of novel strategies for targeting Gram-negative bacteria, including drug-resistant
strains 139.
A central impediment to the development of new antibiotics/antimicrobials is that by the time
that a new therapeutic has passed through clinical trials, resistant bacteria have emerged putting at
risk the investment necessary for the development. It is evident that investigation of novel
antimicrobials must include consideration of the likelihood of resistance development.
Evolutionary pressures lead to generation of drug resistance among bacteria; however, these
pressures also provide direction for the development of antimicrobials that are unlikely to engender
resistance 135,140.
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The ubiquity of endogenous antimicrobial peptides (AMPs) and the diversity of their primary
sequences argue that they have played an important role in innate immunity for eons, that they
have evolved independently dozens of times and that their mechanisms of action allow them to
remain efficacious as antimicrobial agents even with extended bacterial exposure

141

. Although

there are multiple mechanisms by which AMPs exert their antibacterial activities, in general AMPs
are cationic and facially amphiphilic (e.g., they display cationic groups on one face of the molecule
with hydrophobic side chains on the opposing face), and they interact with bacterial membranes
142

. Due to the broad-spectrum bactericidal activity of many AMPs and the idea that bacteria will

not readily become resistant, multiple AMPs have entered clinical trials for treatment of a number
of disease states

128,143,144

. However, there are challenges in clinical use of peptide therapeutics

including relatively high costs of large-scale production and susceptibility to degradation by
proteases 114,145.
The structures of colistin, AMPs and ceragenins have common features: multiple cationic
groups and substantial hydrophobic character. All three types of antimicrobials are known to
interact with bacterial membranes. Consequently, the emergence of highly colistin-resistant
bacteria leads to the questions: (1) Are colistin-resistant bacteria also resistant to AMPs and
ceragenins? (2) Does generation of resistance to colistin occur at the same rate as potential
generation of resistance to AMPs and ceragenins? (3) Since the primary mechanism for bacterial
resistance to AMPs and ceragenins is through modification of the lipid A portion of
lipopolysaccharide (LPS)

146,147

, how important are these modifications in resistance of Gram-

negative bacteria to colistin?
To address these questions, we have compared the susceptibility of colistin-resistant, clinical
isolates of Klebsiella pneumoniae to colistin, representative AMPs (LL-37, cecropin A and
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magainin 1) and representative ceragenins. Our initial focus on K. pneumoniae was due to its
known pathogenicity and its ability to transfer resistance genes to other Gram-negative bacteria
148,149

. To determine the relative rates at which Gram-negative bacteria become resistant to these

antimicrobials, we have serially exposed colistin-susceptible, reference strains of K. pneumoniae,
Pseudomonas aeruginosa and Acinetobacter baumannii to colistin and ceragenin CSA-131 (a
second generation ceragenin) and monitored susceptibility to these antimicrobials. After up to 30
periods (24 h) of exposure to the antimicrobials, susceptibilities of the strains were determined
with colistin, CSA-131 and LL-37. Strains that showed increased MICs with colistin and CSA131 were grown in large quantity, LPS from these strains was isolated, truncated to lipid A, and
structural modifications of lipid A, relative to lipid A in the reference strains, were determined by
mass spectrometry. The same methods were used to characterize lipid A from the clinical isolates
of K. pneumoniae.
Through these studies we found that high levels of resistance to colistin (MICs of 16 to >100
times the MICs with reference strains) do not correlate with comparable resistance to AMPs and
ceragenins. We also found that upon serial exposure of Gram-negative bacteria to colistin or CSA131, these bacteria became highly resistant to colistin (MICs increasing from 1-2 µg/mL to over
300 µg/mL) in a relatively short time, while modest increases in MICs (e.g., from 1 to 4 µg/mL)
with the same strains were observed with CSA-131 over 30 days of exposure. Characterization of
lipid A from susceptible and resistant strains showed the expected modifications of the glycolipid
in the resistant strains; namely, increased fatty acid content and formation of phosphate esters with
4-aminoarabinose or ethanolamine. These modifications were found in the lipid A from the clinical
isolates of K. pneumoniae and from the Gram-negative bacterial serially exposed to colistin and
CSA-131. Nevertheless, while these strains were highly resistant to colistin, they were either
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marginally resistant or fully susceptible to ceragenins and AMPs. These results suggest that lipid
A modifications (increased lipid content and phosphate ester formation with 4-aminoarabinose or
ethanolamine) increase MICs with colistin, ceragenins and AMPs, but these modifications do not
appear to be responsible for the very high levels of colistin resistance seen in clinical isolates and
with the Gram-negative bacteria serially exposed to colistin. These results also indicate that there
is little or no cross resistance between colistin and ceragenins.

3.2

Materials and methods

3.2.1

Materials

Six clinical isolates of K. pneumoniae were obtained from the Antibacterial Resistance
Leadership Group (ARLG, Newark, NJ); colistin-susceptible, reference strains of K. pneumonia
(ATCC 13883), Acinetobacter baumannii (ATCC 19606) and Pseudomonas aeruginosa (ATCC
27853) were obtained from American Type Culture Collection (ATCC, Manassas, VA).
Ceragenins CSA-13, CSA-131, CSA-44, CSA-138, and CSA-142 (Fig 1) were synthesized from
a

cholic

acid

scaffolding

as

previously

50

described

.

LL-37

(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES),

cecropin

A

(KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH2),

and

1

magainin

(GIGKFLHSAGKFGKAFVGEIMKS), all with > 95% purity, were purchased from Anaspec
(Fremont, CA) and used without further purification. Colistin (polymyxin E), Mueller–Hinton
broth (MH) and Mueller–Hinton agar (MHA) were purchased from Sigma–Aldrich (St Louis, MO,
USA).

3.2.2

Susceptibility testing
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Minimum inhibitory concentrations (MICs) were determined using a broth microdilution
method in a 96-well microdilution plate according to the Clinical Laboratory Standards Institute
protocol

150

. Briefly, two-fold dilutions of antibacterial agents (colistin, LL-37, cecropin A,

magainin 1, and ceragenins) in MH were dispended in separate wells of a 96-well plate. Aliquots
(100 µL) of a prepared inoculum were added, and plates were incubated at 37 °C for 18-20 h. Also,
negative and positive controls were included for each set of MIC measurements. The lowest
concentrations of antibacterial agents inhibiting the visible growth of bacteria were used as the
MICs. Minimum bactericidal concentrations (MBCs) were determined by taking 10 μL from each
well and plating on MHA. The MBC was defined as the lowest concentration of an antibacterial
agent giving no visible colonies after 24 h incubation at 37 °C.

3.2.3

Serial passage of bacteria with colistin and CSA-131

Serial passaging of K. pneumoniae (ATCC 13883), P. aeruginosa (ATCC 27853) and A.
baumannii (ATCC 19606) were performed according to the protocol described previously
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.

Briefly, MICs (24 h) for the strains were determined, and bacteria growing at the highest
concentrations of the antimicrobials were used to inoculate fresh medium. This process was
repeated every 18-24 h. MICs were recorded every 24 h, and concentrations of the antimicrobials
were adjusted to allow determination of MICs.

3.2.4

Time–kill curve analysis

Aliquots (100 μL) of inoculated MH (1 × 106 CFU/mL) were added to separate wells on a 96well plate. CSA-131 was added, at a concentration of the MIC, two times the MIC (2xMIC), four
times the MIC (4xMIC), and eight times the MIC (8xMIC), to the wells, and resulting mixtures
were incubated at 37 °C. Aliquots (10 µL) were removed at varied intervals (0, 1, 2, 4, 8, 12, and
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24 h), serially diluted in PBS, plated on MHA and incubated. Bacterial counts were made after 24
h at 37 °C. A negative control, including only bacteria in MH without the ceragenin, was used for
measurement of uninhibited growth. Time-kill curves were plotted by log10 CFU/mL mean colony
counts versus time. Ceragenins were considered bactericidal at a three-log reduction (CFU/mL) or
greater relative to the initial inoculum 152.

3.2.5

Scanning electron microscopy (SEM)

To observe the effect of ceragenins on cell membranes, K. pneumoniae ATCC 13883 was
cultured to mid-log phase and washed three times with PBS. Bacteria were re-suspended in PBS
(OD600 = 0.2). CSA-131 (25 or 50 μg/mL) was added and the mixtures were incubated at 37 °C
for 1 h. A control was prepared by incubating the bacterial suspension without adding CSA-131.
After collection via centrifugation, cells were washed with PBS three times. Gluteraldehyde (2.5%
(w/v)) was added to fix the cells at 4 °C overnight. Resulting material was washed five times with
PBS at 5000 rpm for 10 min using a microhematocrit centrifuge (Hettich Mikro 20, Hettich,
Tuttlingen, Germany) to remove the glutaraldehyde. Osmium tetraoxide (0.5 mL) was used as a
second fixative reagent, and samples were stored at 4 °C overnight. Cells were washed with PBS
five times at 14000 g for 8 min. A graded ethanol series including 10%, 30%, 50%, 70%, 90% (1
time), 100% (3 times) and HMDS (2 times) for 15 min each was used to dehydrate the cells.
Samples were collected by centrifuge each time and the supernatant was discarded after each
centrifugation. Finally, samples were exposed to air in a desiccator at room temperature for 24 h.
To minimize the effect of dehydration on the cell membranes, drying through a CO2 critical point
dryer (Tousimis 931.GL, Research Corp, Rockville, MD, USA) and lyophilizer were applied.
Interestingly, no differences in the quality of images obtained by either air-drying or critical point
dryer were observed. Dried bacterial specimens were sputter-coated with 5-10 nm of a Gold37

Palladium

alloy

and

visualized

under

a

scanning

electron

microscope

(FEI Helios NanoLab 600 SEM/FIB, Hillsboro, Oregon, USA) 82.

3.2.6

Transmission electron microscopy (TEM)

Primary sample preparation of TEM was done according to the method described in the SEM
preparation. Fixation with osmium tetraoxide was performed for 2 hours rather than overnight, the
pellets were washed three times with PBS. Washed cells were embedded in agarose low melt
temperature and after being solidified, they were cut into small cubes of around 1 mm3 and placed
in a vial containing distilled water. Dehydration through the same graded ethanol series used in
SEM was done followed by acetone (3 times). The samples were then immersed in 2:1 and 1:2
mixture of acetone: epoxy resin respectively and rotated for 1h for infiltration. The mixture was
then replaced by 100% epoxy resin and incubated at 60°C overnight. Afterwards, samples were
sectioned using an ultra microtome (MT-X; RMC, Tucson, AZ, USA), stained with uranyl acetate
and lead citrate solutions, and observed with a STEM (FEI Helios NanoLab 600 STEM/FIB,
Hillsboro, Oregon, USA).

3.2.7

Isolation and analysis of lipid A

Lipid A samples were isolated using the TRI Reagent method
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and analyzed via mass

spectrometry (ESI, negative ion mode, Agilent 6230 Series TOF Spectrometer). Using this method,
we found the isolated lipid A showed loss of one phosphate group; consequently, a minor
modification was applied to the published isolation method: heating time of extracted
lipopolysaccharide was changed from 1 h to 30 min at 100 °C in order to obtain the diphosphate
form of lipid A. With this modification to the published procedure, the mass spectral analyses gave
results for lipid A comparable with other published studies 154-156.
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3.3

Results

3.3.1

MICs and MBCs of colistin, AMPs and ceragenins

In an initial set of experiments, the MICs of colistin, LL-37, cecropin A, magainin 1, and
ceragenins (CSA-13, CSA-131, CSA-44, CSA-138, and CSA-142) against colistin-resistant,
clinical isolates of K. pneumoniae were determined and compared to those with a reference,
colistin-susceptible strain of K. pneumoniae (ATCC 13883) (Table 3-1). The clinical isolates gave
MICs of 16 to 200 µg/mL with colistin, and MICs with LL-37 and magainin 1 were relatively high
against the reference strain as well as the clinical isolates. MICs were lower and less varied with
cecropin A and the ceragenins, and only small changes in MIC were observed with cecropin A and
CSAs -13, -44, and -131 with the various strains.
Table 3-1: MICs of colistin, AMPs and CSAs against a standard strain of K. pneumoniae (ATCC 13883) and
colistin-resistant, clinical isolates.

To verify that the activity of the ceragenins is bactericidal, MBCs of two lead ceragenins,
CSA-44 and CSA-131, were determined with the colistin-resistant isolates. These results are
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shown in Figure 3-1. These results show that both ceragenins are bactericidal at relatively low
concentrations, with CSA-44 demonstrating bactericidal activity at concentrations only slightly
above those of the corresponding MICs.

Figure 3-1: Ceragenins are bactericidal against colistin-resistant K. pneumoniae. MBCs of CSA-44 and CSA-131
against six clinical isolates of colistin-resistant K. pneumoniae and a reference strain (ATCC 13883).

3.3.2

Time-kill assays

Time-kill assays were performed to further differentiate between bactericidal and
bacteriostatic activities using ceragenins CSA-44 and CSA-131. The rates of antimicrobial activity
of these ceragenins against selected colistin-resistant strains ARLG-1127 and ARLG-1389 were
compared to those with the reference strain (ATCC 13883) (Figure 2-1). Only minor differences
were seen in the kinetics of bactericidal activity among the colistin-resistant and colistinsusceptible strains, again suggesting that colistin resistance does not significantly influence
susceptibility to ceragenins. At two times the MICs for both ceragenins, the inoculum was
decreased by at least three logs within one to two hours. At four times the MICs, the inoculum was
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decreased to the detection limit (two logs) within the same time frame. At eight times the MICs
(data not shown), results were comparable to those at four times the MICs.

Figure 3-2: Rates of bactericidal activity of ceragenins are similar among colistin-resistant and colistinsusceptible strains. Time-kill curves with CSA-44 and CSA-131 against colistin-resistant K. pneumoniae strains
(ARLG-1127 and ARLG-1389) and colistin-susceptible strain ATCC 3883. Detection limit is 2 logs (CFU/ml).

3.3.3

SEM

Ceragenins selectively target bacterial membranes

35

, and to visualize the impact of a lead

ceragenin, CSA-131, on membrane morphology, bacteria treated with the ceragenin were
subjected to scanning electron microscopy (SEM) (Figure 3-3). In the control without ceragenin
treatment, cells displayed the expected rod shape, although some surface roughness was observed
as a result of the dehydration process (Figure 3-3 A). Nevertheless, there were substantial changes
in the morphology of cells treated with CSA-131 (Fig Figure 3-3 B and Figure 3-3 C). Disruptions
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in the cell membrane are evident along with increased roughness on the cell surface. These changes
in morphology are dependent on the ceragenin concentration. Additionally, ceragenin-treated cells
are shortened relative to untreated cells suggesting that ceragenin treatment prevented K.
pneumoniae from reaching a regular length 33.

Figure 3-3: SEM images of K. pneumoniae (ATCC13883).(A)Control .(B)Treated with 25μg/ml CSA-131. (C)
Treated with 50 μg/ml CSA-131 (magnification 50,000).

3.3.4

TEM

Membrane disintegration of K.pneumoniae ATCC 13883 treated with CSA-131 was observed
via TEM (Figure 3-4). In the control sample, the typical round to ellipse shapes (depending on the
sectioning direction) of K.pneumoniae with an evenly distributed cytoplasmic content was shown
(Figure 3-4 A). However, exposure of the bacteria to the ceragenin evidently caused the
disintegration of the membrane cells with significant blebbing and forming vesicles (Figure 3-4 B
& C). Furthermore, ceragenin induced an obvious collapse in the plasma membrane, consequently
creating denser intracellular components (Figure 3-4 B). Interestingly, treatment with higher
concentrations of ceragenin formed substantial morphological alterations, including breaking the
cell and releasing cytoplasmic components, making the cells seem empty inside (Figure 3-4 C)
35,54

.
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Figure 3-4: TEM images of K. pneumoniae (ATCC13883).(A)Control .(B)Treated with 25μg/ml CSA-131. (C)
Treated with 50 μg/ml CSA-131 (magnification 35000).

3.3.5

Serial exposure of Gram-negative bacteria to colistin and CSA-131

To compare the rates at which K. pneumoniae and two other Gram-negative pathogens (A.
baumannii and P. aeruginosa) acquire resistance to colistin and a lead ceragenin (CSA-131), these
strains were serially exposed to both antimicrobials. Initially, all three strains were fully
susceptible to colistin and the ceragenin (MICs of 1.0 or 2.0 µg/mL). At each 24 h time point,
MICs were determined, and bacteria surviving at the highest concentration of antimicrobial were
used for the subsequent MIC measurement. By 10 days (24 h time periods), the MICs of colistin
against all three genera of bacteria rose to 350 µg/mL or higher Figure 3-5. Relatively small
changes in MIC were observed with CSA-131 over the course of 30 days of exposure. Beginning
and ending MICs are shown in Table 3-2.
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Figure 3-5: MICs of colistin and CSA-131 against K. pneumoniae, A. baumannii and P. aeruginosa after the
number of days (24 h periods) of exposure.

At the end of the serial passaging experiments (10 days for colistin and 30 days for CSA-131),
the MICs of the resulting organisms were determined with colistin, CSA-131 and AMPs LL-37,
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magainin 1 and cecropin A. These results are shown in Table 3-2. Notably, CSA-131 retained
activity against the highly colistin resistant strains. In contrast, relatively modest resistance to
CSA-131 (1 to 8 times the MIC with the parent strain) translated into increased MICs for colistin
(16 to 32 times the MIC with the parent strain). Resistance to colistin also increased MICs with
AMPs (1.3 to 4 times the MIC with the parent strain). Finally, resistance to CSA-131 translated
into comparable resistance to AMPs (2.3 to 8 times the MIC with the parent strain). These results
suggest that colistin resistance includes mechanisms that do not strongly impact susceptibility to
CSA-131 or the AMPs tested.
Table 3-2: MICs of colistin, CSA-131, LL-37, magainin 1, and cecropin A with susceptible standard strains of K. pneumoniae, A.
baumannii, and P. aeruginosa and with strains serially exposed to colistin or CSA-131.
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3.3.6

Characterization of lipid A modifications in clinical isolates of K. pneumoniae and bacteria
serially exposed to colistin and CSA-131

The lipid A portion of LPS is a primary target of colistin 157, ceragenins 54 and AMPs 158, and
lipid A modifications have been observed as a mechanism for resistance generation to these
antimicrobials

138,151,156,159,160

. Lipid A modifications include phosphate ester formation with 4-

aminoarabinose and/or ethanolamine, which decrease the net negative charge of lipid A. To
determine how modification of lipid A from K. pneumoniae correlated with resistance to colistin
and CSA-131, LPS was isolated from three of the clinical isolates and bacteria serially exposed to
colistin and CSA-131. The LPS was truncated to yield lipid A, and modifications to lipid A were
observed via mass spectrometry. Observed masses are shown in Table 3-3 (mass spectra are shown
in Supplementary Materials). Comparable masses have been observed for parent and modified
lipid A 154-156.
Table 3-3: Masses of isolated lipid A from colistin-susceptible (ATCC 13883) and colistinresistant
strains of K. pneumoniae and bacteria serially exposed to colistin and CSA-131
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3.4

Discussion
A central concern in the development of novel antimicrobial agents is the rapidity with which

bacteria generate resistance, and this concern contributes to the paucity of development of new
antibiotics. Since higher organisms have co-evolved with bacteria, the mechanisms by which high
organisms control bacterial growth may provide guidance for development of antimicrobial agents
to which bacteria do no readily generate resistance. AMPs represent one of the key means by which
higher organisms control bacterial growth. As mimics of AMPs, ceragenins share structural
features with these peptides; specifically, multiple cationic (positive) charges juxtaposed with
hydrophobic structure. Notably, colistin shares these structural features. However, while AMPs
and ceragenins are active against Gram-positive bacteria, colistin and the polymyxins in general
are only weakly active against these organisms. This observation argues that, at least for Grampositive bacteria, colistin has a different mechanism of action than AMPs and ceragenins.
Nevertheless, all three classes of antimicrobials are active against Gram-negative bacteria, which
leads to the concern that colistin resistance translates to resistance to AMPs and ceragenins. The
studies presented herein lay this concern to rest; highly colistin-resistant bacteria largely remain
susceptible to AMPs and ceragenins.
The ceragenins tested in these studies and cecropin A gave MICs in the single µg/mL range,
and MICs remained in this range with colistin-resistant clinical isolates (Table 3-1). The clinical
isolates were up to hundreds of times more resistant to colistin than the reference strain, while the
MICs with LL-37 and magainin 1 increased by factors of ca. 2-3. Thus, some cross resistance is
evident, but not to the magnitude observed with colistin.
Further characterization of the most active ceragenins, CSA-131 and CSA-44, demonstrated
the potent bactericidal activity of these compounds (Figure 3-1and Figure 3-2) SEM and TEM
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(Figure 3-4) confirmed earlier studies demonstrating that ceragenins interact with bacterial
membranes. Morphological changes to Gram-negative bacterial membranes are a hallmark of the
activity of many AMPs, and we have shown, via TEM, that similar changes occur in bacterial
membranes upon treatment with a ceragenin
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. The SEM images (Figure 3-3) provide a three-

dimensional representation of these changes.
Serial exposure of Gram-negative pathogens to colistin demonstrates the rapidity with which
these organisms generate resistance (Figure 3-5). MICs rose to 350 µg/mL within 10 days of serial
passaging. In contrast, only small changes in MIC with CSA-131 were observed (Table 3-2). CSA131 retained activity against the highly colistin-resistant bacteria, while the MICs with AMPs
increased by factors of two to eight. Bacteria that were serially exposed to CSA-131 displayed
resistance to colistin (increases by factors of 16 to 32), but their MICs with colistin were much
lower (32 µg/mL) than those serially exposed to colistin. Together, these data suggest that there
may be some common resistance mechanisms among colistin, AMPs and ceragenins, but that the
mechanism(s) that bacteria employ to become highly resistant to colistin is very different from
mechanism(s) used to increase MICs with AMPs and ceragenins.
Two-component systems (e.g., PhoP/PhoQ and PmrA/PmrB) are known to instill resistance
to AMPs

161

, and this resistance is mediated by changes to the structure of lipid A resulting in

incorporation of aminoarabinose and/or ethanolamine

154,158

. For example, in Salmonella

typhimurium this modification is caused by two-component signal transduction systems including
PhoP-PhoQ and PmrA-PmrB

161

. The presence of positive charges on AMPs activates PhoQ,

which is a membrane-associated protein kinase, and activated PhoQ phosphorylates PhoP, which
leads to upregulation of a host of proteins including PagP leading to the addition of palmitate to
membrane-associated lipid A. This change increases the hydrophobic character of lipid A and
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membrane stiffness. The same signal transduction system also leads to further modification of lipid
A through formation of phosphate esters with ethanolamine and L-4-amino arabinose

156,163,164

.

These changes decrease the net negative charge of the membrane and further decreases the affinity
of AMPs to the bacterial membrane. These defenses, however, are metabolically costly to bacteria,
and absent AMPs or other threats, bacteria shut down these systems and exist in AMP-susceptible
forms. It is also interesting to note that although resistance to AMPs has been observed in vitro,
no evidence of resistance in vivo has been observed to this point 41.
The action of MCR-1, characterized as a cause of colistin resistance, has also been proposed
to cause addition of ethanolamine to the parent structure 138, although in a recent study of colistinresistant, clinical isolates of K. pneumoniae, plasmid-associated genes mcr-1 and mcr-2 were not
detected

133

. These changes to lipid A lead to a decrease in the overall negative charge on the

surface of the bacteria and a subsequent a loss of affinity for positively charged antimicrobials. In
a previous study, we observed that serial exposure of Gram-negative bacteria to CSA-13, a first
generation ceragenin, led to modifications of lipid A with aminoarabinose and increases in MIC
151

. Characterization of lipid A from three colistin-resistant, clinical isolates of K. pneumoniae

showed aminoarabinose or ethanolamine modification to lipid A (Table 3-3). Similar
modifications were observed with K. pneumoniae serially exposed to colistin and CSA-131. These
modifications appear common to bacteria resistant to colistin or serially exposed to CSA-131.
However, these changes do not correlate with the high levels of resistance to colistin, suggesting
that another mechanism renders these bacteria highly colistin resistance.
The highest increase in MIC observed after serial exposure (30 days) to CSA-131 came with
K. pneumoniae (an increase from 1.0 to 8.0 µg/mL); changes with A. baumannii and P. aeruginosa
were smaller (Table 3-2). Serial exposure of Gram-negative bacteria to CSA-13 led to much larger
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increases in MIC (MICs > 20 µg/mL). As noted, this resistance was correlated with
aminoarabinose modifications to lipid A 151. CSA-131 has a longer lipid chain than CSA-13, and
we hypothesize that this longer lipid chain allows CSA-131 to interact more strongly with
membranes containing modified lipid A than CSA-13. Ultimately, this stronger interaction with
CSA-131 would allow more effective traversal of the outer membrane and subsequent targeting of
the cytoplasmic membrane.

3.5

Conclusions
While specific mechanisms for resistance of Gram-negative bacteria to polymyxins, including

colistin, have been identified, multiple mechanisms likely influence resistance 162. At least one of
these mechanisms causes very high resistance to colistin but does not appear to impact
susceptibility to AMPs and ceragenins. Lipid A modifications may impact the antimicrobial
activity of colistin, AMP and ceragenins modestly, but they do not account for the very high MICs
for colistin with clinical isolates of K. pneumoniae and Gram-negative bacterial strains serially
exposed to colistin. The fact that lead ceragenins (CSA-44 and CSA-131) retain bactericidal
activity against highly colistin-resistant bacteria provides further support for development of these
compounds as broad-spectrum antibacterial agents in multiple potential clinical applications.

3.6

Appendix A
Supporting information for susceptibility of colistin-resistant, Gram-negative bacteria to

antimicrobial peptides and ceragenins.
Mass spectra (ESI, negative ion mode, Agilent 6230 Series TOF Spectrometer) of lipid A
isolated from the indicated strains of K. pneumoniae. Col-R strain is K. pneumoniae (ATCC 13883)

50

serially exposed to colistin for 10 days. CSA-R is K. pneumoniae (ATCC 13883) serially exposed
to CSA-131 for 30 days.
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Appendix B
Proposed structures for lipid A isolated from the indicated strains that match the mass spectral

data. Changes from the parent structures are in red. Locaton of acylation (addition of a fatty acid)
and phosphate ester formation may not reflect exact structure (i.r., mass spectral data do not
provide positional information for modifications).

ATCC 13883
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ARLG 1389, ARLG 1349
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ARLG 1360
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Col-R (Colistin Resistant made by serial passaging)

CSA-R (CSA resistant made by serial passaging)
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Chapter 4

Proteomic analysis of resistance of Gram-negative bacteria to chlorhexidine

and impacts on susceptibility to colistin, antimicrobial peptides and ceragenins

4.1

Introduction
Chlorhexidine (Figure 4-1) is a potent antiseptic agent that has been in use since the 1950s 165.

It is used extensively in healthcare settings in hand washing, patient bathing, treatment of gingivitis,
skin antisepsis, and other antimicrobial applications 166. Chlorhexidine is sparingly soluble in water,
and thereby normally formulated with either acetate or gluconate to form water-soluble salts.
Chlorhexidine has been found to have antibacterial, antifungal, and even some anti-viral activities
167

. Although chlorhexidine has proven to be an effective antimicrobial agent in hospital settings,

it has limitations. While data show that chlorhexidine is active against planktonic bacterial cells,
it is less effective against biofilms. After treatment of methicillin resistant S. aureus (MRSA) and
multi-drug resistant (MDR) Pseudomonas aeruginosa biofilms grown on hospital grade-surfaces,
these pathogens were shown to maintain up to 11% and 80% of their cell viability respectively 168.
Additionally, recent studies found that various clinical isolates of Klebsiella pneumoniae, from
before and after the widespread use of chlorhexidine, show a significant difference in susceptibility
to the antimicrobial

169,170

. Notably, it has been shown that development of resistance is stable;

bacteria do not revert to susceptible forms after being grown for an extended time in antimicrobialfree medium, suggesting that resistance is mutational rather than adaptational 169.
Due to the prevalent use of chlorhexidine, especially in clinical settings, there has been
increasing concern about whether repeated exposures of bacteria to sub-lethal doses of
chlorhexidine is a factor in the emergence of multi-drug resistant bacteria

171

. For example,

Bhardwaj et al, found that serial exposure of vancomycin-resistant Enterococcus faecium to
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chlorhexidine resulted in reduced susceptibility to other membrane-targeting antimicrobials such
as daptomycin 172. Of particular concern is the role of exposure to chlorhexidine in generation of
colistin resistance. The prevalence of Gram-negative, drug-resistant bacteria has resulted in
increased use of colistin (Figure 4-1), which is considered an antibiotic of “last resort.” However,
colistin resistant organisms have been increasingly isolated from clinical settings 173,174. Wand et
al.

170

recently reported cross-resistance between chlorhexidine and colistin. They found that in

chlorhexidine-adapted strains of K. pneumoniae, the minimum inhibitory concentrations (MIC)
for colistin increased by a factor between 16 and 32 with five of the six strains tested. However,
when colistin-resistant K. pneumoniae were tested for chlorhexidine susceptibility, Wand et al.
found that MICs of chlorhexidine were the same with colistin-susceptible and colistin-resistant
strains. On the other hand, Curiao et al. 175 reported that at least in Salmonella, there are multiple
mutations leading to chlorhexidine resistance that are not necessarily associated with colistin
resistance.
Cross resistance of bacteria to chlorhexidine and colistin may be due to common features of
these antimicrobials. For example, both are cationic (positively charged) with hydrophobic
functionality. Notably, most endogenous antimicrobial peptides (AMPs, representative sequences
are shown in Figure 4-1) also display these features: cationic groups juxtaposed with hydrophobic
side chains 14,176. We recently reported 177 that highly colistin-resistant bacteria are susceptible to
both AMPs and non-peptide mimics of AMPs, termed ceragenins. This finding led to the question
of whether generation of chlorhexidine resistance results in cross resistance to ceragenins and
AMPs. Reported herein are investigations of the means by which Gram-negative bacteria become
resistant to chlorhexidine and how this resistance influences susceptibility to colistin, AMPs and
ceragenins. Rather than focus on mutations, changes to the proteome were investigated to obtain
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an understanding of multiple possible alterations in gene expression that lead to resistance. We
found that, as expected, induction of resistance in Gram-negative bacteria to chlorhexidine resulted
in decreased susceptibility to colistin; nevertheless, organisms remained susceptible to ceragenins.
Changes to the proteome of chlorhexidine-resistant organisms, relative to a parent strain, were in
the outer membrane proteins as well as proteins associated with chaperones, efflux pumps, flagella
and cell metabolism.

Figure 4-1: Structures of chlorhexidine, colistin and sequences of LL-37, cecropin A and magainin 1.

4.2

Material and methods

4.2.1

Materials

K. pneumoniae (ATCC 13883), Acinetobacter baumannii (ATCC 19606) and P. aeruginosa
(ATCC 27853) were obtained from the American Type Culture Collection (ATCC, Manassas,
VA). Chlorhexidine, colistin (polymyxin E), congo red and coomassie brilliant blue dyes were
purchased from Sigma–Aldrich (St Louis, MO, USA).

60

4.2.2

Susceptibility testing

MICs were determined using a broth microdilution method in a 96-well plate according to the
Clinical Laboratory Standards Institute protocol (2006) as described in detail in section 3.2.2

4.2.3

Serial passage of bacteria with chlorhexidine

Serial passaging of bacteria was performed according to a protocol described in section 3.2.3.

4.2.4

Colony morphology assay

MHA plates were made in 60 x 15mm petri dishes with the addition of Congo red (40 mg/L)
and Coomassie brilliant blue (20 mg/L) dyes. Bacterial cultures were grown overnight in MH broth
at 37 °C. An aliquot of bacterial culture (1 μL) was then spotted onto the MHA dyed plates and
incubated at 37 °C for 24 h 178. Images were acquired using a stereo microscope (Stemi 2000,
Zeiss).

4.2.5

Proteomic sample preparation

Three independent studies were performed for the proteomics analyses and one single colony
was used for each independent study. Both wild-type (ATCC 27583) and drug-resistant P.
aeruginosa were cultured in TSB (25 mL) to an OD600 nm of 0.5. Cells were pelleted at 3750 x
g for 10 min at room temperature followed by three washes with ice-cold PBS. Cell pellets were
lysed in 1% sodium dodecyl sulfate (1 mL) in Tris buffer (50 mM, pH 8). Cells were briefly
sonicated to further lyse the cells. Protein concentration was determined by bicinchoninic acid
(BCA) protein assay (Thermo Fisher Scientific, Waltham, MA, USA). Protein digestion was
carried out using filter-assisted digestion. Aliquots of 50 μg of protein were transferred to
centrifugal filters (30 kD molecular weight cutoff), denatured with guanidine (100 μL, 6 M
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guanidinium hydrochloride, 100 mM Tris, pH 8.5), and centrifuged for 15 min at 14000 x g. This
step was repeated three times to remove SDS entirely. Cell lysate was reduced by DTT (20 mM in
6 M guanidinium hydrochloride) at 65 °C for 5 min. After cooling for 5 min, alkylation was
performed with iodoacetamide (50 mM, 1 h incubation at room temperature in the dark). The
mixture was then washed two times with ammonium bicarbonate buffer (25 mM, pH 8.5). The
washed, alkylated protein sample was re-suspended in ammonium bicarbonate (ABC, 100 μL)
followed by overnight digestion at 37 °C with trypsin (1 μg, Sigma-Aldrich Proteomics Grade).
After trypsin digestion, peptides were isolated by spinning down the mixture (14,000 x g, 30 min.)
with one rinse of the filter using ABC (100 μL, centrifugation 14,000 x g for 30 min.). The
combined filtrate was vacuum dried using a speedvac (Sorval). The dried sample was immediately
re-dissolved in 50 μL of buffer (0.1% formic acid in Optima-grade water) for mass spectrometry
analysis 179.

4.2.6

Mass spectrometry data acquisition

Mass spectrometry data were collected using an Orbitrap Fusion Lumos mass spectrometer
(Thermo Fisher Scientific, Waltham, MA, USA) coupled to an EASY-nLC 1200 liquid
chromatography (LC) pump (Thermo Fisher Scientific, Waltham, MA, USA). A capillary RSLC
column (EASY-spray column pepMap ® RSLC, C18, 2 μm, 100 Å, 75 μm × 25 cm) was used for
separation of peptides. The mobile phase was comprised of buffer A (0.1% formic acid in Optima
water) and buffer B (Optima water and 0.1% formic acid in 80% acetonitrile).
Elution of peptides was performed at 300 nL/min with the following gradients over 2 h: 3–
25% B for 80 min; 25–35% B for 20 min; 35–45% B for 8 min; 45–85% B for 2 min and 85% for
8 min. Data were acquired using the method described by Peng et al
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180

. Briefly, using the top

speed method (3 s cycle) and a resolution of 120,000 at 200 m/z, a full scan MS was obtained in
the orbitrap with a target value of 3e5 and a maximum injection time of 60 ms. Detection of
fragment ions in the linear ion trap was performed with a target AGC value of 1e4 and a maximum
injection time of 250ms.
Label-free quantification (LFQ) values were obtained using PEAKS (version 8.5) and the
Swiss-Prot validated P. aeruginosa proteome (5638 sequences May 2018) with a reverse sequence
decoy database concatenated and included during the search. After the removal of contaminants,
low scoring peptides and reverse matches, the LFQ values for the top 3 peptides were summed and
transformed by a logarithm of 2. The proteins were then separated into wild type and mutant groups,
and only those with at least three correct LFQ values were used for quantification. Accordingly,
two-tailed heteroscedastic t-tests were conducted to compare wild type versus mutant groups. The
acquisition of gene ontology terms and functional clusters, as well as the identification of
molecular functions and biological process, was conducted using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) and Uniprot. Information about protein-protein
interaction networks was retrieved from STRING (v10).

4.3

Results and Discussion

4.3.1

Susceptibility of tested Gram-negative bacteria to antimicrobials

Our results in Chapter 3 has shown that Gram-negative bacteria become resistant to colistin
following exposure to a sublethal concentration of colistin; however, colistin resistance does not
correlate with higher MIC levels for AMPs or ceragenins. To determine whether resistance to
chlorhexidine also leads to cross-resistance against other antimicrobials, Gram-negative strains
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were serially exposed to chlorhexidine for 10 days with MIC determination every 24 h. Serial
exposure of Gram-negative bacteria to chlorhexidine resulted in a rapid four- to eight-fold increase
in MICs of chlorhexidine within 10 days (Figure 4-2 ).

Figure 4-2: MICs of chlorhexidine against A. baumannii, P. aeruginosa and K. pneumoniae after the number of
days exposure to chlorhexidine.

MICs of AMPs (LL-37, cecropin A, magainin 1), lead ceragenins (CSA-44 and CSA-131)
and colistin were measured with the chlorhexidine resistant strains (Table 4-1). Notably, the
chlorhexidine-resistant organisms showed decreased susceptibility to colistin (8- to 32-fold
increases in MICs) in spite of not having been exposed to colistin. In contrast, MICs of
representative AMPs were the same with the original strains and the chlorhexidine-resistant
organisms. Similarly, the MICs of lead ceragenins (CSA-44 and CSA-131) were unchanged with
the original and chlorhexidine resistant bacteria. Although chlorhexidine-resistant Gram-negative
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bacteria showed decreased susceptibility to colistin, as earlier reported by Wand et al. 170 and seen
in our studies, colistin-resistant Gram-negative bacteria did not show an increased MIC with
chlorhexidine (data not shown). Overall, these results support the idea that exposure of Gramnegative bacteria to chlorhexidine can lead to cross-resistance to colistin, while susceptibilities to
AMPs and ceragenins remain unchanged.
Table 4-1: MICs of chlorhexidine, colistin, CSA-131, CSA-44, LL-37, magainin 1, and cecropin A with
susceptible standard strains of K. pneumoniae, A. baumannii, and P. aeruginosa and with strains serially exposed to
chlorhexidine and colistin.

CHX: chlorhexidine, Col: colistin. All tested bacteria are serially exposure to chlorhexidine for ten passages. All the MICs are
results of three independent experiments. nm: not measured.

4.3.2

Colony morphology

Control strains of each type of Gram-negative bacteria produced colonies of circular and
smooth morphology (Figure 4-3 A-C). The serially passaged strains of A. baumannii and K.
pneumoniae, however, formed colonies of irregular shape and had rough surfaces (Figure 4-3 DF). Although P. aeruginosa serially exposed to chlorhexidine produced colonies which were
circular, they also had slightly rough surfaces and formed undulating margins. All three serially
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passaged strains grew larger colonies that covered more surface area than their respective controls.
These changes in morphology may be a response to LPS modifications. For example, in
Pseudomonas stutzeri, it has been shown that chlorhexidine resistance accompanies a loss of lowmass LPS species in SDS-PAGE gels. Because these strains showed cross-resistance, the shift to
higher-mass LPS suggests that multidrug resistance is accompanied by LPS production which
favors larger polysaccharide components

181

. And, as demonstrated in Gram-negative Vibrio

cholerae, colony morphology can shift from smooth to rough in response to extracellular
polysaccharide changes

182

. The connection between extracellular polysaccharides and colony

morphology is further supported by Salmonella enterica, which shifts from rough to smooth
morphology when short O-antigen chain LPS production is up-regulated 183. Because capsular
polysaccharides have been shown to shield K. pneumoniae from polymixins, including colistin 184,
the increased mass of the polysaccharides contained within LPS may be the bridge between
resistance to the two classes of antimicrobials, either by introducing additional mass or by
changing the organization of the capsule. Generally, proposed mechanisms of colistin resistance
in Gram-negative bacteria involve LPS modifications

185,186

. Thus, chlorhexidine resistance

potentially brings about colistin resistance through one or more modifications to LPS.
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Figure 4-3: Colony morphology of A. baumannii and, P. aeruginosa and K. pneumoniae upon exposure to
chlorhexidine. Bacterial strains P. aeruginosa (A, D), A. baumannii (B, E), and K. pneumoniae (C, F) were serially
passaged with chlorhexidine (D-F) and the resulting colony morphology was compared with untreated colonies (AC).

4.3.3

Proteomics

Proteomics has been established as an effective method of analyzing biological processes and
is particularly valuable for examining resistance to antibiotics 187,188. For P. aeruginosa, a recent
study has unveiled several differences in protein expression associated with low and high levels of
ciprofloxacin resistance 189. On the whole, though, proteomic data on chlorhexidine-resistant P.
aeruginosa remain scarce, in particular regarding cross-resistance with colistin, for which, to the
best of our knowledge, no data on differential expression inherent to resistance are yet available.
We have evaluated cross-resistance between colistin, chlorhexidine, AMPs and their mimic,
ceragenins, and we further analyzed the proteome of chlorhexidine-resistant P. aeruginosa using
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reference strain ATCC 27853 for comparison.
We used label-free quantitation to compare the relative concentrations of proteins within the
proteome of wild-type and chlorhexidine-resistant P. aeruginosa. We observed substantial
alterations of the proteome of the resistant strain relative to the wild-type strain, with several highly
abundant proteins reduced in relative concentration and increased in a collection of proteins with
distinct connections to antibiotic resistance as outlined below. A total of 330 proteins (out of 528
proteins) were differentially expressed at a significant level (2-fold-change, p < 0.05), following
exposure to chlorhexidine. Identification, function and biological functions of some proteins
differentially expressed between the chlorhexidine-resistant and wild-type P. aeruginosa are listed
in Table 4-2 in the same order that they are mentioned in the text. Large changes in protein
expression indicate that the general protein concentration can vary dramatically in response to
treatment 183,188.
We searched for relationships among the most upregulated (12.5% of the total differentially
expressed) and the most downregulated (12.5% of the total differentially expressed) proteins and
assigned them to functional clusters. The numbers of differentially expressed proteins for each
cluster are shown in Figure 4-4. Functional clusters containing the largest number of upregulated
proteins are involved in microbial metabolism in diverse environments, carbon metabolism, ATP
binding, nucleotide binding and translation of proteins. Conversely, functional clusters containing
the largest number of downregulated proteins include nucleotide-binding, ATP-binding,
cytoplasm and nucleotide phosphate-binding proteins.
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A
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B

Figure 4-4: Functionally similar proteins (colored groups) among the most significantly (≥2 fold changes, p<
0.05) upregulated (A) and downregulated (B) proteins of chlorhexidine-resistant P. aeruginosa against wild type. Each
bar within the colored group represents a different functional connection between proteins within that group.
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4.3.3.1

Modifications in membrane proteins following exposure to chlorhexidine

Due to the positive charge on chlorhexidine, its initial interactions with Gram-negative
bacteria are thought to occur at negatively-charged regions of LPS. Further, reduced susceptibility
to chlorhexidine has been previously reported in association with modifications in the cell
membrane, including modifications to LPS 181,190. LPS modifications that have been associated
with decreased bacterial susceptibility to cationic agents, such as chlorhexidine, include chargereducing modifications in LPS and size reduction of the O-antigen polymer 190.
In this study, several changes in the expression of proteins associated with the cell membrane
were noted following chlorhexidine exposure. As shown in Table 2, OprF was one of the most
highly upregulated proteins in our study. OprF is a multifunctional protein that helps maintain cell
shape, interacts with peptidoglycan layers, and is associated with forming non-specific channels
for passive diffusion of ions, small polar nutrients and antibiotics 191,192. It has been shown that
inactivated OprF decreases virulence and increases outer membrane vesicle formation in P.
aeruginosa 193. Additional work has been done on the role of OprF in modifying quorum sensing
and promoting virulence factor production in P. aeruginosa. Loss of functioning OprF was
accompanied by loss of quorum sensing network activity and virulence factor production 194.
Protein network analysis (Figure 4-5) showed that the relative increase in OprF is
accompanied by an increase in LptD concentration, a protein involved in the assembly of LPS for
OM biogenesis. Mutant, non-functional LptD in P. aeruginosa increases the permeability of the
outer membrane and results in compromised barrier function 195. Therefore, upregulation of LptD
in our data suggests that exposure to chlorhexidine decreases the permeability of the OM in P.
aeruginosa.
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Figure 4-5: The most significantly upregulated proteins in chlorhexidine-resistant P. aeruginosa are highly
interconnected. The connections between OprF to LptD, TolB, OprI, and LolA suggests that LPS production may be
significantly changed (relevant proteins are in the top right corner.)

OprF also is connected to TolB (Figure 4-5), part of the Tol-Pal system, which contributes to
the biogenesis of the OM and plays a key role in maintaining OM integrity. A significant
upregulation of TolA, another part of Tol-Pal system, was also observed upon exposure of the cells
to chlorhexidine in our proteomics data. Biochemical studies have identified interactions between
TolA and OM porins 196, which are consistent with our results where both TolA and OM porin F,
OprF, are upregulated.
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Studies have shown that mutant tol genes in E. coli increased susceptibility to antibiotics 197.
The absence of TolA in E. coli K-12 has been shown to cause a substantial reduction in the surface
expression of O antigen (O7-specific) LPS and less lipid A-core oligosaccharide. Its absence is
also correlated with attenuated growth rate and dramatic morphological changes 198. In tol mutants
of Vibrio cholera, filamentation has also been reported 199. This observation is consistent with our
morphological study in which treatment with chlorhexidine caused dramatic morphological
changes and altered flagella protein regulation in the Gram-negative bacteria.
An increase in the expression of a ligase enzyme associated with peptidoglycan biosynthesis
(MurD) was also observed. Upregulation of MurD may result in a protective modification by
increasing the thickness or cross-linking the peptidoglycan layer, which subsequently reduces the
efficacy of chlorhexidine by affecting its transportation. Mur enzymes have been an attractive
target for the development of antibacterial inhibitors owing to the fact that these enzymes are
highly conserved molecules specific to bacteria with a known structure and function. However, no
Mur inhibitors are clinically used as antimicrobials 200.
Of note, a protein which increased with chlorhexidine resistance was PagL, a deacetylase
which removes the R-3-hydroxymyristate at position 3 of lipid A. PagL is activated by the
phoP/phoQ two-component system, a regulatory system controlling genes for virulence within
Salmonella

201,202

.

Though

usually

inhibited

by

4-amino-4-deoxy-L-arabinose

and

phosphoethanolamine modifications of lipid A, PagL deacetylation of lipid A has been tied to
increased polymyxin resistance in Salmonella strains lacking these modifications. In a later study,
overexpression of a pagL-specific sRNA, Sr006, was shown to increase pagL mRNA, lipid A
deacetylation, and polymyxin B resistance in P. aeruginosa. The same study also demonstrated
that a pagL knockout resulted in decreased polymyxin B resistance 203. Therefore, upregulation of
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PagL in chlorhexidine-resistant P. aeruginosa indicates that the mechanism of action for resistance
to chlorhexidine could be partly in common with that of polymyxins.
Interestingly, protein network analysis (Figure 4-5) suggested that PagL is connected to LpxD,
a significantly upregulated protein which is involved in lipid A biosynthesis along with LpxC,
another upregulated protein. Previous MALDI-TOF analysis of the lipid A extracted from RamAoverexpressing strains of K. pneumoniae revealed that RamA increases colistin/polymyxin
resistance levels 204. This increase was accomplished through RamA directly binding to lipid A
biosynthesis genes such as lpxC causing lipid A structural modifications. However, no RamA
overexpression was observed in our study. We also found several outer membrane lipoproteins
including LolA, BamD and OprI upregulated following chlorhexidine exposure. These results
suggest that the increased lipoprotein synthesis of BamD and OprI might be required for
appropriate sorting of lipoproteins by carrier proteins, like LolA, to the outer membrane under
certain stress conditions such as antibiotic exposure 205.

4.3.3.2 Altered chaperone protein regulation following exposure to chlorhexidine
The Clp chaperones and proteases are highly conserved proteins found across the prokaryotes,
in the mitochondria of eukaryotes and the chloroplasts of plants. Previous studies showed that
ClpB is a chaperone associated with resistance to high temperature in E. coli. Furthermore,
inactivation of the clpB gene of Leptospira interrogans resulted in reduced virulence and
attenuated the in vitro growth of the cells under stress conditions, suggesting that ClpB plays a
major role in bacterial survival under stress conditions 206. Upregulation of ClpB upon exposure to
chlorhexidine was also observed in our study, confirming that ClpB is essential for stress tolerance
against inducing factors like antimicrobial agents where proteins tend to unfold and aggregate. Clp
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protease, a periplasmic chaperone protein, was also reported to be upregulated in biofilm upon
chlorhexidine treatment 207.
One of the protein translocation systems through the inner membrane involves Sec proteins
in a chaperone-based pathway where immature proteins are targeted to a Sec translocase such as
SecG, SecE, and SecY using the chaperone SecB for transport across the inner membrane. Our
data showed upregulation of SecG and SecB while SecA was downregulated. Previous reports
showed that loss of function of SecG leads to a significant increase in membrane depolarization,
hydroxyl radical formation and cell death in aminoglycoside-treated cells. The redox-responsive
two-component system (Arc) was also shown to have an associated role 208. Interestingly, our
proteomics profile revealed the upregulation of ArcA, ArcB and ArcC that encode arginine
deiminase, ornithine carbamyltransferase and carbamate kinase, respectively. The Arc twocomponent system contains ArcB, a quinone-sensitive sensor kinase that controls the redox state
of the cellular quinone pool via modulating the phosphorylation state of the transcription factor
ArcA 208,209.

4.3.3.3 Efflux pump activity following exposure to chlorhexidine
A previous proteomics study correlated an increase in the expression of MexCD-OprJ efflux
systems with a reduction in susceptibility to ciprofloxacin in P. aeruginosa 189. Additionally, the
transcriptome of P. aeruginosa revealed that MexCD-OprJ efflux pump was significantly
upregulated after treatment with chlorhexidine 210. Another study showed that increased
expression of SmvA, an efflux pump of the major facilitator superfamily (MFS), is associated
with increased resistance to chlorhexidine in K. pneumoniae 211. However, in our study, exposure
to chlorhexidine did not increase the relative expression of SmvA or Mexcd-Oprj efflux systems.
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Although we did not find upregulation of SmvA or Mexcd-Opri, we found that multidrug
resistance protein MexA was significantly upregulated. MexA functions as the periplasmic linker
component of the MexAB-OprM efflux system that confers multidrug resistance, possibly
indicating that this system plays a role in chlorhexidine response. Conversely, other research has
shown that the overexpression of efflux pumps does not impact the antimicrobial efficacy of
chlorhexidine, and it has been proposed that this is largely due to the limited solubility of
chlorhexidine in the bacterial membrane core 212.

4.3.3.4 General cell metabolism following exposure to chlorhexidine
Proteomic platform analysis showed that many proteins associated with energy metabolism
and many enzymes associated with glycolysis, fatty acid biosynthesis, and the TCA cycle were
upregulated in the resistant strain. For example, upregulation of AceE and AceF, two enzymes
involved in the conversion of pyruvate to acetyl-CoA and CO2, was observed. In addition, proteins
associated with acetyl-CoA carboxylase such as AccD and AccB were also upregulated. These
proteins are involved in the first step of the subpathway that synthesizes malonyl-CoA from acetylCoA. Furthermore, significant upregulation was observed in proteins FadA, FabV and AcpP1,
which are all involved in lipid metabolism. FadA catalyzes the final step of fatty acid oxidation,
in which acetyl-CoA is released. FabV catalyzes the reduction of a carbon-carbon double bond in
an enoyl moiety that is covalently linked to Acp as an acyl carrier protein of the growing fatty acid
chain. Consistent with our results, increased expression of several proteins associated with fatty
acid synthesis, such as Acp, was also observed in biofilm of Delftia acidovorans following
chlorhexidine exposure 208. Finally, a substantial number of proteins associated with the TCA cycle
were upregulated. Succinate-CoA ligase enzymes (SucC and SucD), fumarate hydratase (FumC1),
malate:quinone oxidoreductase 2 (MqO2) and citrate synthase (GltA) were the upregulated
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proteins related to the first step of the cycle. Aconitate hydratase enzymes (AcnA and AcnB) were
the upregulated proteins involved in isocitrate synthesis.
The acquisition of antimicrobial resistance may be energetically costly for bacteria, and in a
normal environment, high-energy expenditure lowers the general fitness of bacteria. Therefore,
bacteria will usually only take on metabolic costs if environmental pressures, such as antibiotics,
dictate its necessity

213

. The upregulation of metabolic proteins by P. aeruginosa shown in this

study could be a result of the intrinsic linkage between bacterial metabolism and antibiotic
resistance.

4.3.3.5 Altered flagella protein regulation in chlorhexidine resistant strain
Of interest in our proteomics data is the upregulation of Pil proteins (PilA, PilG, PilH, PilJ,
PilQ) involved in fimbriae formation and motility. Formation of pili, or fimbriae, has been
correlated with virulence in pathogens such as P. aeruginosa, E. coli, A. baummanii, V. cholerae
and Streptococcus spp. Presence of pili enables bacteria to bind to a surface or tissue, which
initiates interaction with the host and increases biofilm formation 213-215. It has been previously
reported that overexpression of flagellar genes is associated with increased tolerance to
antimicrobial agents, including chlorhexidine, in Salmonella, which may now be extended to
chlorhexidine tolerance in Pseudomonas 190,216,217. Twitching motility is a bacterial movement on
a solid surface that occurs in a wide variety of pathogens including P. aeruginosa. Twitching
motility is mediated by a complex chemosensory pathway including PilG, PilH, PilI, PilJ and PilK
and is also involved in biofilm formation 218,219. The upregulated proteins identified in our study,
including PilG, PilH and PilJ, suggest that exposure to chlorhexidine increased the twitching
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motility which contributes to virulence and biofilm formation. It is known that type IV pili in P.
aeruginosa are assembled from PilA, a single protein subunit, which is transferred out of the cell
via outer membrane secretin PilQ to form fimbrial strands. The upregulation of PilA and PilQ
suggests that the biosynthesis of pili, which is associated with adhesion and accumulation of P.
aeruginosa on surfaces, increased in chlorhexidine-exposed bacteria

220

. Overall, the observed

alterations in Pil proteins in our comparison of the proteomes of chlorhexidine-susceptible and
resistant bacteria are associated with biofilm formation and virulence, suggesting that further
investigation of biofilm formation in chlorhexidine-resistant bacteria would be a meaningful line
of research.
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Table 4-2: Identification, function and biological process of proteins differentially expressed between chlorhexidineresistant and wild type P. aeruginosa.
Accession No.

1

P13794

Protein

Function

Biological Process

Outer membrane

Porin activity,

Adhesion of symbiont to

porin F (OprF)

structural role in

host, ion transport,

determining cell

regulation of cell shapes.

Fold Change

62.38

shape and growth
in low osmolarity
medium.
2

Q9I5U2

LPS-assembly

Assemply of

Gram-negative-

protein

lipopolysaccharid

bacterium-type cell outer

e at the surface of

membrane assembly,

the outer

lipopolysaccharide

membrane.

export, response to

LptD

(LptD)

7.83

organic substance.
3

P50601

Tol-Pal system

Maintains outer

Cell cycle, cell division,

protein

membrane

protein import.

TolB

(TolB)

15.36

integrity during
outer membrane
invagination of
cell division.

4

P50600

Tol-Pal system

Role in outer

Bacteriocin transport,

protein

membrane

cell cycle, cell division.

(TolA)

TolA

invagination
during cell
division,
maintains outer
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285.55

membrane
integrity.
5

Q9HVZ9

UDP-N-

Cell wall

Cell cycle, cell division,

acetylmuramoyl

formation,

cell wall organization,

alanine—D-

catalyzes addition

peptidoglycan

glutamate ligase

of glutamate to

biosynthetic process,

(MurD)

UDP-N-

regulation of cell shape.

3.63

acetylmuramoylL-alanine (UMA).
6

Q9HVD1

Lipid

A

Has 3-O-

Lipid A metabolic

deacylase PagL

deacylase activity,

process,

(PagL)

hydrolyzes ester

lipopolysaccharide

bond at the 3

metabolic process.

Large
Positive

position of lipid
A.
7

Q9HXY6

UDP-3-O-

Catalyzes N-

Lipid A biosynthetic

acylglucosamin

acylation of UDP-

process.

e

3-O-

N-

acyltransferase

acylglucosamine

(LpxD)

with 3-

Large Positive

hydroxyacyl-ACP
as the acyl donor.
8

P47205

UDP-3-O-acyl-

Catalyzes

Lipid A biosynthetic

N-

hydrolysis of

process.

acetylglucosami

UDP-3-O-

ne deacetylase

myristoyl-N-

(LpxC)

acetylglucosamine
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108.97

to UDP-3-Omyristoylglucosa
mine and acetate.
9

10

11

Q9I0M4

P33641

P11221

Outer-

Transports

Chaperone-mediated

membrane

lipoproteins from

protein transport across

lipoprotein

inner membrane

periplasmic space,

carrier

to outer

lipoprotein localization

(LolA)

membrane.

to outer membrane.

Outer

Assembly and

Cell envelope

membrane

insertion of beta-

organization, protein

protein

barrel proteins to

insertion into membrane.

assembly factor

the outer

BamD (BamD)

membrane.

Major

***

***

973.45

Stress-induced

Protein metabolic

152.40

multi-chaperone

process, protein

system involved

refolding, response to

in recovery from

heat.

protein

outer

Large Positive

58.42

membrane
lipoprotein
(OprI)
12

Q9HVN5

Chaperone
protein

ClpB

(ClpB)

heat induced
damage.
13

Q9HV52

Protein-export

Participates in

Intracellular protein

membrane

protein export by

transmembrane transport,

sequence

protein secretion, protein

similarity.

transport by the Sec

protein
(SecG)

SecG

complex.

81

Large
Positive

14

Q9HU56

Protein-export

Molecular

Protein tetramerization,

protein

chaperone that

protein transport.

SecB

Large Positive

binds precursor

(SecB)

proteins and
maintains them in
a translocationcompetent state.
Binds receptor
SecA.
15

Q9LCT3

Protein

Sec protein

Protein import, protein

translocase

translocase

targeting, protein

subunit

complex, couples

transport by the Sec

hydrolysis of ATP

complex.

SecA

(SecA)

0.84

to protein transfer,
SecB receptor.
16

P13981

Arginine

Conversion of L-

Arginine catabolic

deiminase

arginine to L-

process to ornithine,

(ArcA)

citrulline.

arginine deiminase

70.59

pathway.
17

P08308

Ornithine

Catalyzes

Arginine biosynthetic

carbamoyltransf

phosphorolysis of

process via ornithine,

erase, catabolic

citrulline in

arginine catabolic

(ArcB)

catabolism of

process to ornithine,

arginine.

arginine deiminase

650.66

pathway, urea cycle.
18

P13982

Carbamate

Synthesizes CO2

Arginine deiminase

kinase (ArcC)

and NH3 from

pathway, carbamoyl

82

290.09

19

P52477

carbamoyl

phosphate catabolic

phosphate.

process.

Multidrug

Periplasmic linker

Protein

resistance

of MexAV-OprM

homooligomerization,

efflux system,

response to antibiotic.

protein

MexA

(MexA)

35.89

efflux pump for nhexane and pxylene efflux.

20

Q59637

Glycolytic process.

3014.55

Glycolytic process.

40.67

Synthesizes

Fatty acid biosynthetic

129.73

malonyl-Coa from

process, malonyl-CoA

acetyl-CoA.

biosynthetic process.

Pyruvate

Catalyzes

dehydrogenase

conversion of

E1 component

pyruvate to

(AceE)

acetyl-CoA and
CO2.

21

Q59638

Dihydrolipoylly

Catalyzes acetyl-

sine-residue

CoA and enzyme

acetyltransferas

N6-

e component of

(dihydrolipoyl)lys

pyruvate

ine to CoA and

dehydrogenase

enzyme N6-(S-

complex (AceF)

acetyldihydrolipo
yl)lysine.

22

Q9HZA7

Acetylcoenzyme

A

carboxylase
carboxyl
transferase
subunit

beta

(AccD)

83

23

P37799

Biotin carboxyl

Facilitates transfer

Fatty acid biosynthetic

carrier

of the carboxyl

process.

of

protein

acetyl-CoA

180.37

group to form

carboxylase

malonyl-CoA in

(AccB)

fatty acid
biosynthesis.

24

Q9HZJ3

3-ketoacyl-CoA

Catalyzes the final

thiolase (FadA)

step of fatty acid

Fatty acid beta-oxidation.

Large
Positive

oxidation (in
which acetyl-CoA
is released).
25

Q9HZP8

Enoyl-[acyl-

Catalyzes the

Fatty acid biosynthetic

carrier-protein]

reduction of a

process.

reductase

carbon-carbon

[NADH]

double bond in

(FabV)

the final reduction

87.20

of the elongation
cycle of fatty acid
synthesis (FAS
II).
26

O54439

Acyl

carrier

Fatty acid chain

Lipid A biosynthetic

carrier.

process.

Succinate—

Provides

Nucleoside triphosphate

CoA

succinate binding

biosynthetic process,

[ADP-forming]

specificity in the

protein

subunit

coupling of

autophosphorylation,

hydrolysis of

tricarboxylic acid cycle.

protein

1

46.21

(AcpP1)
27

P53593

(sucC)

ligase

beta

84

1522.01

succinyl-CoA
with synthesis of
ATP or GTP in
TCA cycle.
28

Q51567

Succinate—

Provides

Nucleoside triphosphate

CoA

coenzyme A and

biosynthetic process,

[ADP-forming]

phosphate binding

tricarboxylic acid cycle.

subunit

specificity in the

ligase

alpha

(SucD)

44.3522

coupling of
hydrolysis of
succinyl-CoA
with synthesis of
ATP or GTP in
TCA cycle.

29

Q9I587

Fumarate

Catalyzes the

Fumarate metabolic

hydratase class

stereospecific

process, malate

II 1 (FumC1)

interconversion of

metabolic process,

fumarate to L-

tricarboxylic acid cycle.

68.94

malate.
30

Q9HVF1

Probable

Catalyzes the

Ethanol oxidation,

malate:quinone

redox reaction

tricarboxylic acid cycle.

oxidoreductase

between (S)-

2 (Mqo2)

malate and a
quinone to form
oxaloacetate and a
reduced quinone.

85

923.77

31

P14165

Tricarboxylic acid cycle.

316.01

Catabolism of

Anaerobic respiration,

40.00

short chain fatty

propionate metabolic

acids via TCA

process (methylcitrate

cycle, 2-

cycle), response to

methylcitrate

oxidative stress,

cycle I, catalyzes

tricarboxylic acid cycle.

Citrate Synthase

Catalyzes the

(GltA)

formation of
citrate (and CoA)
from oxaloacetate
and acetyl-CoA.

32

Q9I3F5

Aconitate
hydratase

A

(AcnA)

isomerization of
citrate to
isocitrate.
33

Q9I2V5

Aconitate
hydratase
(AcnB)

B

Catabolism of

Propionate catabolic

SCFAs via TCA

process (2-methylcitrate

cycle, 2-

cycle), tricarboxylic acid

methylcitrate

cycle.

cycle I,
isomerization of
citrate to
isocitrate,
hydration of 2methyl-cisaconitate to
(2R,3S)-2methylisocitrate.

86

1161.97

34

P04739

Fimbrial protein

Assembles type

Cell adhesion involved

(PilA)

IV pili.

in single-species biofilm

105.67

formation, pathogenesis,
regulation of calciummediated signaling,
single-species biofilm
formation on inanimate
substrate, type IV pilusdependent motility.
35

P46384

Protein

PilG

(PilG)

Pilus biosynthesis

Phosphorelay signal

and twitching

transduction system.

46.57

motility, receives
environmental
signals and
transduces them
to pilus assembly
machinery.
36

P43501

Protein

PilH

(PilH)

Member of the

Phosphorelay signal

signal

transduction system.

81.69

transduction
system that
regulates twitch
motility and pilus
function.
37

P42257

Protein
(PilJ)

PilJ

Member of the
signal
transduction
system that

87

Chemotaxis.

182.73

regulates twitch
motility and pilus
function.
38

P34750

Fimbrial

Biogenesis and

Protein secretion, type

assembly

secretion of type

IV pilus biogenesis.

protein
(PilQ)

PilQ

Large Positive

IV fimbiae,
essential for
formation of pili.

4.4

Conclusion
We have demonstrated that prolonged exposure of Gram-negative bacteria to chlorhexidine

results in significantly reduced susceptibility to colistin but not to AMPs and ceragenins. This
suggests that there may be a specific mechanism for resistance of Gram-negative bacteria to
chlorhexidine that causes even higher resistance to colistin but does not affect susceptibility to
AMPs and ceragenins. These observations are consistent with the reported decrease in
susceptibility of chlorhexidine-resistant K. pneumoniae to colistin 211. The fact that lead ceragenins
(CSA-44 and CSA-131) retain bactericidal activity against highly colistin and chlorhexidine
resistant bacteria is further support for the development of these compounds as broad-spectrum
antibacterial agents to potentially be used in multiple clinical applications.
To understand the changes to Gram-negative bacteria that lead to chlorhexidine and colistin
resistance but do not impact AMPs and ceragenins, an in-depth quantitative proteomic study was
performed with a parent strain of P. aeruginosa and its chlorhexidine-resistant progeny. It is likely
that proteins involved in resistance to chlorhexidine function similarly in other Gram-negative
bacteria. Our study suggests that increased expression of membrane proteins such as OprF, LptD,
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and the Tol-Pal system is responsible for chlorhexidine resistance, but this is not the only pathway
contributing to resistance. For example, chlorhexidine resistance is also associated with
upregulation of PagL, which is affected by the two-component regulatory system phoP/phoQ.
Additionally, upregulation of flagella proteins, chaperones and proteins associated with energy
metabolism were also observed in the chlorhexidine-resistance pathway. Upregulation of some of
these proteins also correlates with colistin resistance. Co-resistance with colistin suggests that LPS
modification along with changes in expression of associated membrane proteins could be involved
in the primary mechanism of chlorhexidine resistance. The fact that exposure of Gram-negative
bacteria to chlorhexidine may lead to colistin resistance and possible drug resistance among Grampositive organisms suggests that wide-spread use of chlorhexidine should be reconsidered. In order
to decrease the speculated effect of chlorhexidine on the development of colistin-resistant strains,
application of other antimicrobials such as ceragenins could be a safe choice considering its lower
risk of cross-resistance.
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Chapter 5

Ceragenins are active against drug-resistant Candida auris clinical isolates in

planktonic and biofilm forms

5.1

Introduction
Candida auris has emerged as a global threat; from the initial report from in Japan in 2009, it

has spread and been isolated on five continents

221-223

. C. auris can be a substantial cause of

nosocomial infections in some settings and associated with high levels of mortality

224,225

. Of

particular concern is the drug resistance found among many isolates. Resistance to azole antifungal
agents with clinical isolates is common, and resistance of some strains of C. auris to all three
classes of commonly used antifungals (azoles, polyenes and echinocandins) has been observed
226,227
228

. The emergence of this pathogen has led to efforts to better track and characterize infections

, and it provides a strong impetus for the development of novel antifungal agents active against

drug-resistant organisms 229.
Higher organisms have faced threats from fungal pathogens for hundreds of millions of years,
and evolutionary pressures have yielded antifungal innate-immune functions effective against
organisms in both planktonic and biofilm forms. Antimicrobial peptides (AMPs) constitute a key
component of these innate-immune defenses, and AMPs from a variety of sources have shown
potent antifungal activities 230,231. The prevalence of AMPs, in organisms ranging from mammals
to amphibians to insects to plants, suggests that AMPs retain antimicrobial activities over extended
periods without generation of widespread resistance. Recognizing the antifungal activities of
AMPs and their anticipated retention of potency with extensive use, substantial efforts have been
made to develop antifungal AMPs for clinical use
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231

. Impediments to clinical use include the

relative high cost of large-scale preparation of peptide therapeutics as compared to small molecules
and the instability of linear peptides in the presence of ubiquitous proteases.
Recently, antifungal activities of selected ceragenins were reported

82

, with MICs of

ceragenins comparable to or below those measured with amphotericin B, fluconazole and AMPs
omiganan and LL-37 with multiple strains of Candida albicans. Fungi in the genera of
Paecilomyces,

Cryptococcus,

Aspergillus,

Scedosporium,

Rhizopus,

Blastomyces

and

Apophysomyces also proved susceptible to the ceragenins tested. Atomic force microscopy images
of C. albicans untreated and treated with ceragenin CSA-13 showed changes in surface
morphology of cells treated with the ceragenin, which were interpreted as showing membrane
activity. Studies of mechanisms of antifungal activities of AMPs have concluded that membrane
perturbation plays a key role 83,232, while increases in damage by reactive oxygen species (ROS)
and attenuation of mitochondrial functions, leading to apoptosis, have been observed 84,86,233. In a
recent study, magnetic nanoparticles adorned with either the AMP LL-37 or CSA-13 resulted in
generation of ROS in Candida spp 87.
Considering the need for novel antifungal agents in the face of the growing threat of C. auris
infection, our objectives in the studies described herein were to determine the antifungal activity
of selected ceragenins against isolates of C. auris collected by CDC and to compare these activities
with those of representatives of the three major classes of antifungal agents. Activities measured
included both MICs and minimum fungicidal concentrations (MFCs) on planktonic organisms.
Because fungi may grow in sessile form in biofilms, we also measured the activities of selected
ceragenins against established biofilm forms of C. auris. To better understand the antifungal
activities of ceragenins, SEM images of C. auris, with and without ceragenin treatment, were
acquired. Although ceragenins are well tolerated in a variety of routes of administration
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119,120,122,132

, topical application to skin or mucosal tissues to treat fungal infections represents an

attractive use of the antimicrobials. To determine the potential for use in this venue, different
formulations of ceragenins CSA-44 and CSA-131 were evaluated in an ex vivo vaginal porcine
mucosal tissue model infected with C. albicans or C. auris and compared to nystatin or a
commercial cream containing miconazole.

5.2

Materials and methods

5.2.1

Materials and fungal strains

CDC (Atlanta, GA) has catalogued over 100 clinical isolates of C. auris for use in determining
susceptibility patterns, and these were used in initial studies with ceragenin CSA-131. These
isolates represent all four of the known clades of C. auris and originated from various countries.
These isolates were characterized as susceptible or resistant to fluconazole and echinocandins
based

on

the

MICs

published

by

CDC

(https://www.cdc.gov/fungal/diseases/

candidiasis/recommendations.html), although C. auris-specific breakpoints have not yet been
established. Ten additional isolates of C. auris and one strain of C. albicans (ATCC 90028,
Manassas, VA) were used to further characterize susceptibility to other ceragenins. Three
antifungal drugs belonging to the three main classes of commonly used antifungal compounds
including amphotericin B (Fisher Scientific, Pittsburgh, PA), fluconazole and caspofungin
(Sigma-Aldrich, St. Louis, MO, USA) were used in comparison. The culture media used included
Sabouraud dextrose broth (SDB) or agar (SDA) and 1640-RPMI (Sigma-Aldrich, St. Louis, MO,
USA) buffered at pH 7.0 with 165 mM of MOPS (Sigma-Aldrich, St. Louis, MO, USA). Published
protocols for growth of Candida spp. have used either SDB or RPMI 234-236, and to observe any
medium-dependent changes in susceptibility, MICs and MFCs were measured in both media.
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5.2.2

Determination of susceptibility profiles of planktonic fungi

MICs of the C. auris strains were measured according to the broth microdilution protocol from
the Clinical and Laboratory Standards Institute M27-A3 document

237

. With the entire CDC

collection, RMPI medium was used in the measurement; inocula of 0.5 to 2.5 x 103 CFU/mL were
prepared and used to seed pre-prepared drug plates containing CSA-131. These plates were
incubated at 35 °C and read after 24 hours. With the smaller collection (10 isolates), two different
media, SDB and RPMI, were used to evaluate the antifungal activity of all four classes of
antifungal compounds used in this study. MFCs were determined by plating 10 µL from each well
of the MIC plate (after 24 h incubation) on SDA plates and measuring the lowest concentration of
the antibiotic which eliminated 99.9% (three-log reduction) of the colonies formed on the plates
after 48 h of incubation at 35 °C 238.

5.2.3

Determination of susceptibility profiles of fungal biofilms

To quantify the biofilm formed by clinical isolates of C. auris and determine the sessile
susceptibility profile of ceragenins, metabolic activity within biofilms was imaged using 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) as described by Moss
et al 236. In this assay, metabolic activity of cells in the biofilm is measured based on their reduction
of XTT. Initially, biofilms were formed in a sterilized polystyrene flat-bottomed 96well microtiter plates (Sarstedt, USA) incubated at 35 °C for 48 h and washed three times with
PBS to remove planktonic cells. Ceragenins were then added to the wells in a concentration range
of 1-128 µg/mL and incubated for 24 h. A 10 mM menadione (Sigma-Aldrich, St. Louis, MO,
USA) solution was prepared in 100% acetone and added to an XTT solution (0.5 mg/mL) to
achieve a final concentration of 1 µM menadione. Aliquots of the XTT/menadione solution (100
μL) were added to each well containing biofilm and negative control wells. Plates were wrapped
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in aluminum foil and incubated at 37 °C for 2 h. Aliquots of the supernatant (70 µL) were removed
from each well and the optical density was measured at 490 nm using a microtiter plate reader.
Corresponding optical density values for each strain were subtracted from the negative control
values to calculate sessile minimum inhibitory concentrations (SMICs). The SMIC50 and SMIC80
represent the concentration of the drug where the absorbance of the biofilm decreased by 50% or
by 80%, respectively, compared to the biofilm formed by the same strain in the absence of the
drug. Results are from three independent experiments.

5.2.4

Scanning electron microscopy of C. auris

To observe the effect of ceragenins on cell membranes, C. auris CDC 390 was cultured to midlog phase and washed three times with PBS. Fungi were re-suspended in PBS (OD600=0.2). CSA131 (25 or 50 µg/mL) was added and the mixtures were incubated at 37 °C for 1 h. A control was
prepared by incubating the fungal suspension without adding CSA-131. SEM sample preparation
was performed as described in detail in section 3.2.5.

5.2.5

Confocal laser scanning microscopy

To observe the effects of treatment of fungal biofilms with CSA-131, aliquots (300 µL) of C.
albicans and C. auris CDC383 (106 CFU/mL) were placed into separate single wells in a LabTek® Chamber Slide™ (Nunc, Inc., Naperville, IL, USA) and incubated for 48 h. The biofilms
were treated with CSA-131 (50 µL of a 50 µg/mL solution) and incubated for 24 h at 35 °C. After
incubation, the solution was carefully removed, and the wells were washed three times with PBS.
Biofilms were stained with BacLight Live/Dead Viability Kit (L13152, Molecular Probes, Inc)
according to the manufacturer’s instructions, and observed at 60x magnification using a confocal
laser scanning microscope (Olympus FluoView FV1000).
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5.2.6

Assays in ex vivo tissue

Ex vivo experiments were performed using porcine vaginal mucosal explants as previously
described

235

. Normal healthy porcine vaginal tissue was excised from animals at slaughter

(Theurer’s Quality Meats, Lewiston, UT) and transported to the laboratory on ice. Tissue was
trimmed and collected in RPMI 1640 media supplemented with penicillin (50 IU/mL, MP
Biomedicals, Solon, OH) and streptomycin (50IU/mL, MP Biomedicals, Solon, OH). Antibiotics
were included to decolonize normal flora, which may interfere with biofilm formation. Explants
of uniform size were obtained using a 5 mm biopsy punch. Excess muscle was trimmed away with
a scalpel. After antibiotic washout (3 changes of RPMI 1640 media followed by 30 min incubation
at 37 °C), explants were transferred mucosal side up onto a PET 0.4 μm cell culture insert (BD
Falcon, Franklin Lakes, New Jersey) and inoculated with 2 μL (105 CFU/explant) of C. auris (CDC
390) or C. albicans (ATCC 90028) prepared from overnight cultures in Todd Hewitt Broth.
Following 2 h and 24 h incubation at 37 °C, explants (n=3) were treated with CSA-44L or CSA131L (100 µL, 0.5% active) or CSA-44H and CSA-131H (2% active) in a HEC gel formulation
and subsequently incubated for 24 h at 37 °C. For studies of cream formulations, aliquots of the
test articles (100 µL) were spread evenly over explants. Tissues were suspended in a neutralizing
broth (250 μL, Dey/Engley (HiMedia Laboratories, West Chester, Pennsylvania)), vortex mixed
(highest setting for 4 m), and then serially diluted in PBS (Sigma, St. Louis, MO) and plated or
plated neat. Samples were spread on Tryptic Soy Agar containing 5% sheep blood (BD Falcon,
Franklin Lakes, New Jersey) using a spiral plater (Microbiology International, Frederick, MD)
then incubated for 24 h at 37°C.
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5.2.7

Statistical analysis

Analysis of variance (ANOVA) were performed by Dunnett’s multiple comparison posttest
using the GraphPad PRISM software (GraphPad Software, Inc., La Jolla, CA).

5.3

Results and discussion

5.3.1

Susceptibility of planktonic fungi to ceragenins

The susceptibilities of 100 clinical isolates to a lead ceragenin, CSA-131, were determined,
and the distribution of CSA-131 MIC values ranged from 0.5-1 µg/mL (Table 5-1). The overall
mode was 1 µg/mL and both the MIC50 and the MIC90 were 1 µg/mL. CSA-131 showed activity
against all four clades of C. auris with no variation in activity between the clades. There was no
loss in activity for those isolates which were previously determined to be resistant to fluconazole
and/or an echinocandin.
Table 5-1: MICs of CSA-131 with fluconazole-resistant, fluconazole-susceptible and echinocandin-resistant C. auris
isolates

To verify that other lead ceragenins also demonstrated activity against C. auris, studies were
performed with a smaller collection of isolates and activities were compared to those with a strain
of C. albicans. Both MICs and MFCs were measured in SDB or RMPI with CSA-44, CSA-131,
CSA-142, CSA-144 and representatives of the three major classes of antifungal agents. As
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observed with the larger collection of C. auris isolates, MICs of CSA-131 were either 0.5 or 1.0
µg/mL, and they were similar with CSA-44 and CSA-144 (Table 5-2). MICs were relatively higher
with CSA-142. The strains tested gave relatively high MICs with fluconazole, and one of the
strains (CDC383) showed resistance to caspofungin. As compared to caspofungin, amphotericin
B and fluconazole, the ceragenins gave lower MFCs, suggesting greater fungicidal activity as
compared to these other antifungal agents. Among the representative antifungal agents,
caspofungin is the most closely related to ceragenins; it is a cationic molecule appended with a
lipid chain. Similarly, ceragenins are cationic, and a lipid chain is required for activity.
Nevertheless, caspofungin-resistant C. auris strains (e.g., CDC383) were fully susceptible to
ceragenins. In general, the medium in which MICs and MFCs were determined did not play a
substantial role; with many antifungal agents and organisms, MICs were identical in both media,
as were MFCs.
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Table 5-2: Comparison of the susceptibility (µg/mL) of clinical isolates of C. auris to selected ceragenins and
three major classes of antifungal agents in SDB and RPMI.

5.3.2

SEM of ceragenin-treated fungi

As described above, membrane disruption has been identified as a major mechanism of
antifungal activity of AMPs 232,239, among other possible mechanisms. Changes in cell morphology
upon treatment with AMPs have been attributed to membrane interactions, these include loss of
smooth cell surfaces with marked invagination at high AMP concentrations. Similar
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Figure 5-1: Scanning electron photomicrograph of untreated C. auris CDC390 (A and B) and treated with
CSA-131 25 μg/mL (C and D) and 50 μg/mL (E and F).

morphological changes in C. albicans were observed with the human AMP LL-37 and the
ceragenin CSA-13 82. The impacts of CSA-131 on the morphology of C. auris are shown in Figure
5-1. As with C. albicans treated with LL-37 or CSA-13, CSA-131 alters cell shape; at 50 µg/mL
CSA-131 causes cells to buckle in upon themselves and some cells appear to have merged. These
changes in cell morphology were observed at concentrations well above MFCs, and antifungal
activity may be due to more subtle changes in cell permeability at lower concentrations of the
ceragenin. At MFCs, little or no morphological changes in fungal cells are apparent.

5.3.3

Susceptibility of fungal biofilms to ceragenins

The abilities of bacteria and fungi to form biofilms, in which sessile organisms reside,
contribute to drug resistance and protection of persister organisms that provide sources for chronic
infections. The abilities of C. albicans to form biofilm are well established

240-243

differing results for biofilm-forming propensities of C. auris have been reported
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; however,

244,245

. Using a

measure of metabolic activity, we compared biofilm forming properties of a C. albicans reference
strain to those of four isolates of C. auris (CDC 381, CDC-383, CDC 386 and CDC 390). Biofilms
were grown under identical conditions, and as reported 246, C. auris strains were less efficient than
the C. albicans strain at biofilm formation. Using the XTT-based assay, metabolic activity of the
C. auris biofilms was measured as approximately 50% of that of C. albicans (Figure 5-2).

Figure 5-2: Biofilm formation by four selected strains of C. auris compared to C. albicans (ATCC 90028) at 48 h.

Having established the biofilm-forming characteristics of C. auris isolates, we used metabolic
activity of biofilms to determine the activities of representative ceragenins and antifungals against
sessile organisms making up these biofilms. Concentrations necessary to reduce biofilms by 50
and 80% are shown in Table 5-3. The ceragenins, amphotericin B and caspofungin demonstrated
strong activity against the biofilms, while fluconazole was much less active. Because fluconazole
100

was weakly active against these organism in planktonic form, it is not surprising that biofilms were
less susceptible to this antifungal as compared to others included in the study. Observing
SMIC(80%) results, it is apparent that the sessile form of C. auris CDC390 becomes particularly
resistant to all of the antifungals.
Table 5-3: Susceptibility profiles of sessile fungi (biofilm) to CSA-44, CSA-131 and three antifungal
compounds.

5.3.4

Confocal laser scanning microscopy of fungal biofilms

To observe the antibiofilm properties of a lead ceragenin, biofilms of C. albicans and C. auris
were treated with CSA-131, stained and imaged via confocal microscopy (Figure 5-3. Untreated
biofilms exhibited expected aggregates of live cells, while treated biofilms showed comparable
aggregates of dead cells. As with Gram-negative bacteria 93, the ceragenin was able to penetrate
the extracellular matrix and exert antifungal activity without significantly compromising the
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biofilm morphology. The antibiofilm property of the ceragenins compliments their ability to inhibit
biofilm formation as reported in a recent study in which CSA-131, incorporated into a hydrogel,
prevents biofilm formation on a medical device for extended periods 247.

Figure 5-3: Confocal laser scanning micrographs (60 x magnification) of stained fungal biofilms. Green: live cells;
red: dead cells. A: C. albicans, untreated. B: C. albicans, CSA-131 treated (50 µg/mL). C. C. auris, untreated. D: C.
auris, CSA-131 treated (50 µg/mL).

5.3.5

Antifungal activity of formulated ceragenins in tissue explants

There are many potential applications of novel antifungal agents, and some of the most widely
useful would involve topical application to skin or to mucosal tissues. For these types of
applications, lead ceragenins would need to be formulated into gels or creams.
Hydroxyethylcellulose (HEC, typically used at 2.7% in water) can be used to form a lubricating
gel into which antimicrobial compounds can be formulated. Pluronic F127 is a non-ionic surfactant
that has shown compatibility with ceragenins with concomitant decreases in cytotoxic properties
80,239

. Combining HEC, pluronic and either CSA-44 or CSA-131 at 0.5% (44L and 131L) or 2.0%

(44H and 131H) gave stable, lubricious gels. These percentages of ceragenins are comparable to
those of antifungals incorporated into commercially available antifungal products.
Porcine vaginal mucosal explants were used to determine the antifungal activities of these
gels. Nystatin (a polyene antifungal related to amphotericin B) was used as a comparator and the
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HEC-pluronic combination (vehicle) was used to observe effects of these compounds on the fungi.
Fungal infection with either C. albicans or C. auris was established over 2 and 24 h of incubation,
followed by treatment for 24 h with the test formulations. Over this time course, fungal populations
grew to over 106 CFU per explant (Figure 5-4). In all experiments, the vehicle had no impact on
fungal growth.
At two hours, nystatin decreased fungal counts with C. auris and C. albicans by ca. one log,
but only with C. albicans was this reduction statistically significant. In contrast, both ceragenins,
at both concentrations, significantly reduced fungal counts at two hours, with reductions as great
as five logs (CSA-131 at 2%). At 24 h, nystatin-treated explants supported fungal counts
comparable to controls with both species of fungi. At 24 h, the most potent activity of ceragenins
was observed with C. albicans, with fungal counts significantly reduced relative to both control
and nystatin-treated explants. With the highest concentrations of ceragenin (2%), fungal counts
were reduced by more than four logs. Although the activity of the ceragenins, at 24 h, was not as
dramatic with explants colonized with C. auris, significant reductions (ca. three logs) were
observed with the highest concentration of the ceragenins. Significant reduction was also observed
with the lower concentration (0.5%) of CSA-44.
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Figure 5-4: Antifungal activities of nystatin (100,000 USP nystatin units) compared to HEC/pluronic
formulations of CSA-44 and CSA-131 in porcine vaginal mucosal tissue explants. Log10 CFU reduction from untreated
growth control following 2 h (A and B) and 24 h (C and D) infections of C. auris or C. albicans on porcine vaginal
mucosa (PVM). Data presented are means and standard errors of the means (SEMs). Analysis of variance (ANOVA)
followed by Dunnett’s multiple comparison posttest were performed using the GraphPad PRISM software (GraphPad
Software, Inc., La Jolla, CA). *significantly different from growth control (p<0.5); #significantly different from
nystatin (p<0.5). CSA-44L or CSA-131L: 0.5% active, CSA-44H or CSA-131H: 2% active in a HEC gel formulation.

CSA-44 was also formulated into a cream and compared to commercial Monistat 7 in the
porcine vaginal mucosa infection model. Based on efficacy of the ceragenins in the gel formulation,
a concentration of 1% CSA-44 in a cream was used and compared to Monistat 7 (2% miconazole
in cream formulation). No other formulations were evaluated in this assay. With C. albicans,
Monistat 7 reduced fungal counts by a statistically significant amount at two hours, as compared
to the growth control, but this effect was negligible at 24 h. With this organism, the CSA-44 cream
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formulation reduced counts by more than three logs at two hours and by ca. two logs at 24 h, both
of which measurements were significantly different from both the vehicle and the Monostat 7treated explants (Figure 5-5). Explants colonized with C. auris were not significantly affected by
Monostat-7 treatment at 2 and 24 h. In contrast, the CSA-44-containing cream significantly
reduced C. auris counts at both time points (> 2 log and >1 log reductions, respectively).

Figure 5-5: Antifungal activities of Monistat 7 (2% miconazole) compared to a cream formulation of CSA-44
(1%) in porcine vaginal mucosal tissue explants. Log10 CFU reduction from untreated growth control following 2 h
(A and B) and 24 h (C and D) infections of C. auris or C. albicans on porcine vaginal mucosa (PVM). Data presented
are means and standard errors of the means (SEMs). Analysis of variance (ANOVA) followed by Dunnett’s multiple
comparison posttest were performed using the GraphPad PRISM software (GraphPad Software, Inc., La Jolla, CA).
*significantly different from growth control (p<0.5); ^significantly different from Monistat 7 (p<0.5).
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5.4

Conclusions
The spread of C. auris, the high mortality rates in patients with infection and the high

prevalence of drug resistance among clinical isolates underscore the need for the development of
novel antifungal agents. The mechanisms common to endogenous AMPs provide direction for
investigation of therapeutics that mimic antimicrobial activities that nature has honed over millions
of years. Due to their simple structures, ceragenins are attractive candidates for development of
novel antifungal agents; they can be prepared at a large scale and they are stable in the presence of
ubiquitous proteases. The ceragenins display antifungal activities with C. auris comparable to the
most active agents tested, and they do not show cross resistance with other antifungals. The
ceragenins also retain activity against sessile organism in established biofilms. In formulated forms,
ceragenins are active against high inocula of fungi in mucosal tissue. The substantial antifungal
activities of these ceragenin formulations compared to nystatin and Monistat 7 highlight their
potential for use as novel antifungals for topical or mucosal applications.
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Chapter 6

Preclinical testing of a broad-spectrum antimicrobial endotracheal tube

coated with an innate immune synthetic mimic

6.1

Introduction
Tissues in the airways provide innate immune defenses against microbial colonization, and a

key component of these defenses is the production of antimicrobial peptides (AMPs) 248,249. These
defenses limit microbial transfer from the highly-colonized oropharynx to the nearly sterile lung
tissues. Nearly 50 million patients worldwide are intubated annually with endotracheal tubes
(ETTs) to assist breathing. The abiotic surfaces of ETTs provide a breeding ground on which
microbes can readily form biofilms 250-252, because the surfaces do not provide an innate immune
function comparable to surrounding tissues. Biofilms that form on these abiotic surfaces are a
nidus for continual inoculation of surrounding tissues while providing an avenue for microbial
transfer into the lungs leading to pneumonia. Ventilator-associated pneumonia remains a major
healthcare burden 252,253, adding to lengths of intensive care, costs of hospitalization and increasing
the use of antibiotics. Infections associated with mechanical ventilation lead to endotoxin-driven
inflammation 254, which in turn can result in sepsis and remote organ damage (e.g., acute kidney
injury), brain damage in neonates

255,256

and delirium in elderly patients

257,258

. Prevention of

biofilm growth on ETTs may result in significant clinical improvements, reduced antibiotic usage,
emergence of fewer multidrug resistant bacteria, reduction of endotoxin-driven adverse clinical
outcomes and shorter duration of length of stay in the ICU.
It is increasingly recognized that microbial colonization of ETTs is polymicrobial

250,251,259

.

The presence of different microbial pathogens in close proximity to each other in the biofilm
matrix enables horizontal gene transfer of plasmids encoding for resistance to conventional
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antibiotics and thereby facilitates the emergence of new drug-resistant strains 260,261. Initial studies
of ETT colonization focused on both Gram-positive and Gram-negative pathogens; however, fungi
are now understood to contribute to ETT colonization 250,251,259. Of particular concern are highly
drug-resistant organisms. For example, while colistin is considered the antibiotic of “last resort”
for Gram-negative bacteria, highly colistin-resistant bacteria have been isolated from a variety of
tissues 262-264. These bacteria are generally resistant to other antibiotics, with many characterized
as extended-spectrum beta-lactamase producing organisms. Due to the relatively few antifungal
agents available, recent identification of Candida auris as a drug-resistant fungal pathogen has led
to fears of untreatable infections 265.m
Efforts to prevent ventilator-associated infections have included use of systemic antibiotics
266-268
267

as well as silver-releasing ETTs 269,270. Recent studies by Stulik et al.266 and Burnham et al.

have shown that systemic administration of antibiotics has little effect on airway colonization,

and this ineffectiveness is likely due to the rapidity with which bacteria form biofilms and the
insensitivity of these biofilms to most antibiotics. Silver-releasing ETTs showed promise in
preventing bacterial colonization

269,270

, with a concomitant reduction in risk of infection in

patients ventilated for more than 24 h. However, silver-releasing ETTs have not gained widespread
use in hospitals 270.
An attractive approach for prevention of microbial colonization of ETTs would be to provide
an innate immune-like function on their abiotic surfaces. This function would necessarily mimic
the activities of endogenous AMPs: broad-spectrum antibacterial activity, anti-fungal activity and
the ability to sequester bacterial endotoxins to minimize inflammation. The use of AMPs to
provide an innate immune-like function to ETTs has been proposed 271.
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As mimics of AMPs, ceragenins also associate with endotoxins

63

, inhibiting the processes

that lead to release of inflammatory cytokines. As small molecules, ceragenins can be readily
prepared at a large scale, and because they are not peptide based, they are not substrates for
proteases.

Figure 6-1: Structure of CSA-131(NDSA).

As functional mimics of AMPs, ceragenins are well suited for providing innate immune-like
functions to the abiotic surfaces of medical devices. Herein we describe the incorporation of a lead
ceragenin, CSA-131 (Figure 6-1), into a thin film, comprised of a lubricious hydrogel, on ETTs.
The hydrogel film provides a reservoir of the ceragenin and facilitates controlled release of the
ceragenin over extended periods. As the ceragenin is released, it prevents bacterial and fungal
biofilm formation and sequesters endotoxins. In its optimized form, the coating is applied via dip
coating with a mixture containing the ceragenin, followed by polymerization of the hydrogel. The
resulting coating can be sterilized by ethylene oxide without adduct formation. In vivo experiments
showed that the coated ETT is well tolerated, and no systemic exposure to ceragenin was observed.
The Food and Drug Administration (US) has recognized the need for ETTs that prevent microbial
colonization, and the coated ETT described herein was recently granted Expedited Access Pathway
designation pursuant to the 21st Century Cures Act.
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6.2

Materials and methods

6.2.1

Coating

CSA-131(NDSA) was jet milled (Fluid Energy, Telford, PA) to give particles of less than one
micron in size. The resulting material was added to Hydromer Coating Solution 2018-20M
(Hydromer, Branchburg, NJ) in quantities equal to 10 weight percent relative to the amount of
non-volatile material in the coating solution and remained as a suspension of particles. To prepare
ETT segments, tubes (7.5 mm id, Flexicare, Irvine, CA) were cut into 5 mm segments. For coating,
intact tubes and tube segments were washed with isopropanol and hexanes and fully dried. Tubes
and segments were dip coated, and the coating was then cured at 71.1 °C for 1 h. With tube
segments, weight differences were determined and used to calculate average coating thickness.
Coated tubes and tube segments were subjected to standard ethylene oxide (ETO) sterilization
procedures (Steris, San Diego, CA), and ETO-treated segments were used to quantify ETO adduct
formation with CSA-131 via mass spectrometry (Agilent 6230 TOF, Santa Clara, CA). To
determine the total amount of CSA-131(NDSA) in the coatings, segments (5 mm) of coated ETTs
were immersed (1

mL

) in an acidic solution of isopropanol (90% isopropanol, 10% 1 M HCl in

water) for three 4 h intervals. After each interval, the resulting solution was concentrated under
vacuum, reconstituted in water and the CSA-131 concentration was determined via LC/MS (using
an internal, mass-labeled standard) or HPLC-ELSD. To visualize the coating, coated and uncoated
ETT segments (1 cm) were stained with crystal violet (2% w/v in ethanol) for 30 sec, then rinsed
with distilled water five times. Segments were dried under vacuum for 1 h. Sections (ca. 1 mm)
were cut and imaged with a light microscope (Axiovert 135, Zeiss, Germany) equipped with a
digital camera.
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6.2.2

CSA-131 elution studies

6.2.2.1 Elution from the inner lumen
Coated, intact ETTs (7.5 mm id, 28 cm length) were oriented in a drip flow reactor at a 30˚
angle. The proximal end of the ETT was connected to a peristaltic pump delivering 1 mL/min of
sterile PBS. Aliquots of the aqueous solution were collected from the distal end of the ETT in
separate vessels at time points of 30 and 60 min, 2, 4, 8, 24, 48, 72 and 96 h. The resulting solutions
were lyophilized and reconstituted with minimal water prior to CSA-131 concentration
determination via LC/MS (using an internal, mass-labeled standard) or HLPC-ELSD.
6.2.2.2 Elution from the outer lumen
The ends of intact ETTs (7.5 mm id, 28 cm length) were plugged with stoppers, and the tubes
were placed in a PVC hose (2.5 cm id, 30 cm length) to approximate the size of an adult trachea.
The hose was filled with PBS (120 mL), sealed at the ends with stoppers, and incubated at 37 °C.
The resulting solution was collected and replenished with fresh PBS at 24, 48, 72 and 96 h. The
resulting solutions were lyophilized and reconstituted with minimal water prior to CSA-131
concentration determination via LC/MS (using an internal, mass-labeled standard) or HLPCELSD.

6.2.3

Efficacy tests

6.2.3.1 Microbial cultures
Bacterial and fungal cultures were prepared from fresh colonies placed in media and incubated
overnight at 37 °C. Pseudomonas aeruginosa (PA01, ATCC 47085), MRSA (BAA-41), and
Klebsiella pneumoniae (ATCC 13883) were cultured in trypticase soy broth (TSB). Candida
albicans (ATCC 90028) and C. auris (CDC 0383) were cultured in Sabouraud Dextrose Broth
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(SDB). Bacterial and fungal cultures were pelleted and washed three times in PBS and the resuspended in PBS. Optical density (OD) readings were performed at 600 nm. Aliquots of cultures
were diluted in 10% TSB for bacteria or 10% SDB for fungi to a population of 106 CFU/mL and
103 CFU/mL, respectively.
6.2.3.2 Determination of antimicrobial properties of coated ETTs
To determine antimicrobial properties of CSA-131(NDSA) coatings, coated ETTs were cut to
5 mm segments and placed in sterile culture tubes. Inoculation solutions were prepared containing
106 CFU/mL (bacteria) or 103 CFU/mL (fungi), and these solutions (1 mL) were used to immerse
ETT segments resulting in a surface area to volume ratio of 0.3 cm2/mL. Tubes were capped and
incubated at 37 °C for 24 h. Microbial growth was confirmed when the surrounding growth
medium gave a turbidity greater than 0.5 McFarlands or when less than a three-log reduction was
observed relative to controls with uncoated ETT segments. The latter measurement was made by
removing aliquots (10 µL) from the growth media, serially diluting the aliquots, plating them on
nutrient agar (TSA for bacteria and SDA for fungi), incubating for 24 h at 37 °C with bacteria and
48 h at 35 °C for fungi and counting resulting colonies. All ETT segments were tested in triplicate
with uncoated ETT segments used as controls.
6.2.3.3 Quantification of biofilm growth
Coated ETT segments (5 mm) were treated as described above. For evaluation with mixedspecies inocula, bacterial cultures (106 CFU/mL) were mixed (0.5 mL of each) before addition of
ETT segments, or a fungal culture (103 CFU/mL, 0.5 mL) was mixed with a bacterial culture (106
CFU/mL, 0.5 mL) before addition of ETT segments. At 24 h intervals, ETT segments were
removed (three at each time point), gently rinsed with PBS to remove planktonic organisms,
immersed in neutralizing buffer (1 mL, Dey-Engley, Sigma Aldrich) and sonicated (bath sonicator)
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for 15 min. The resulting solutions were serially diluted and plated on agar (TSA for bacteria and
SDA for fungi), incubated for 24 or 48 h at 35 or 37 °C and colonies were counted.

6.2.4

SEM of microbial biofilms

ETT segments (1 cm) were incubated with bacterial and fungal cultures (1 mL) as described
above for the indicated time periods. Controls were prepared by incubating uncoated ETT
segments with the same cultures for the same time periods. After incubation, segments were gently
washed with Sorensen buffer (0.1 M, pH 7.2) then fixed, dehydrated and sputter-coated as
described in detail in section 3.2.5.

6.2.5

Measurement of endotoxin levels associated with coated and uncoated ETTs

Endotoxin levels were quantified using a Limulus amebocyte lysate (LAL) assay with a kinetic
chromogenic readout (Charles River Laboratories, Charleston, SC). Assays were performed
according to the manufacturer’s instructions with an Escherichia coli endotoxin standard to
establish a standard curve. Responses to the endotoxin standard were measured at varied
concentrations of CSA-131, and no interference in endotoxin quantification was observed.
Uncoated and coated ETT segments (5 mm) were inoculated with P. aeruginosa (PA01, 106 CFU)
in TSB and incubated at 37 °C. Aliquots of the fluid were removed at specified times (0, 4 and 8
h) and assayed for endotoxin. At 24 h, tube segments were removed, gently washed with PBS,
immersed in neutralizing broth and sonicated for 15 min. Aliquots of the resulting broth were
assayed for endotoxin.
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6.2.6

Intubation studies

Six pigs, weighing approximately 35-45 kg, were used in this safety evaluation study. On the
day of the procedure, each animal was anesthetized and prepped acutely. Each animal was
implanted with a coated or uncoated endotracheal tube and monitored under anesthesia for 24 h.
Blood samples were collected at various time points during the study for pharmacokinetic and
cytokine analysis. After the test period, the animals were euthanized and a limited necropsy
performed. The trachea, oropharyngeal area, and collateral structures (lungs) were grossly
examined for abnormalities that may be attributed to the test article.

6.3

Results and discussion
The hydrogel used in the coating is a polyurethane-based, medical-grade, lubricious material

developed by Hydromer, Inc. It is generated, after dip coating, via polymerization of isocyanate
groups upon exposure to moisture and heat. For clinical use of coated medical devices, sterilization
is required, and ETO treatment is the most commonly used method of sterilizing ETTs. Coatings
prepared with CSA-131(NDSA) gave a stable coating (13 ± 2 µm) that showed no detectable
adduct formation (< 1%) by mass spectrometric analysis after ETO treatment.
To image the coating, coated and uncoated ETT segments were soaked (30 s) in a solution of
crystal violet in ethanol. The segments were then washed with water and dried. Coated segments
retained the dye, while uncoated segments remained unstained (Figure 6-2). The stained coating
proved uniform with a thickness of approximately 10 µm.
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Figure 6-2: Microscopy images of the inner lumen of ETT stained with crystal violet. A: uncoated ETT. B:
coated ETT.

The amount of CSA-131(NDSA) added to the coating solution was 10% (w/w) of the nonvolatiles in solution. To quantify the amount of ceragenin in the coating, CSA-131 was extracted
from coated ETT segments using 90% isopropanol/10% aqueous HCl (1 M). From these
experiments, we determined that the total amount of CSA-131 was 39.4 µg/cm2 (6.9 mg on the
entire tube), as determined via mass spectrometry with a mass-labeled internal standard or via
HPLC using ELSD.
CSA-131(NDSA) has limited solubility (< 20 µg/mL) in water, and for the solubility of CSA131 to increase in water, ion exchange must occur (e.g., chloride for NDSA). This ion exchange
process, as well as the structure of the polyurethane, contributes to the controlled release of the
ceragenin from the coating. The rate at which CSA-131 eluted from the coating was determined
using two methods. For the inner lumen, a drip flow procedure was used in which phosphatebuffered saline (PBS) was dripped through intact, coated ETTs at the rate of 1 mL/min, the rate at
which fluids pass through ETTs in the trachea. For the outer lumen, coated ETTs were incubated
in a larger tube of the approximate size of an adult trachea (2.5 cm diameter and 30 cm length).
Rates of elution from the inner lumen (drip-flow method) are shown in Table 1; after the first hour
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of elution, the concentration of CSA-131 dropped below the detection limit (0.25 µg/mL). Elution
from the outer lumen was measured over 96 h, and comparable amounts eluted over each 24 h
period (Table 6-1). Notably, in both the drip flow elution and elution into a static solution, the
concentration of CSA-131 never exceeded 1 µg/mL.
Table 6-1: Elution of CSA-131 from the inner lumen of intact, coated ETTs measured via drip flow (1
mL/min).

*Inner lumen elution measured via drip flow (1 mL/min) with an ETT inner lumen surface area of 74.8 cm2
**Below Detection Limit (DT). Detection limit: 0.25 μg/mL
***Outer lumen elution measured in a static solution (120 mL) with an ETT outer lumen surface area of 99.4 cm2

To determine the efficacy of coated ETTs in preventing microbial growth, bacterial
suspensions (106 CFU/mL) or fungal suspensions (103 CFU/mL) were prepared in growth media,
and segments (5 mm) of coated ETTs were immersed in the media. The suspensions were
incubated at 37 °C for 24 h, and the tube segments were re-challenged every 24 h in fresh growth
media. Two measures of microbial growth were quantified: (1) microbial growth in the
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surrounding medium and (2) microbial biofilm formation on the tube segments. For the first
measure, aliquots were removed from the growth media, serially diluted and plated; with this
measure, continuous testing was possible. In contrast, to quantify biofilm growth, it was necessary
to remove tube segments, gently wash them in PBS and sonicate them in neutralizing broth. Tube
segments thus treated could not be returned for continued study because sonication may have
altered the structure of the coating.
As anticipated, with uncoated tube segments, microbial growth was observed in the growth
media and biofilms formed on the segments. In contrast, coated ETT segments prevented microbial
growth in the surrounding media and prevented biofilm formation for multiple days. Quantification
of microbial biofilm formation on tube segments with representative organisms is shown in Figure
6-3. Duration of activity ranged from four days with P. aeruginosa to 16 days with C. albicans.
During these intervals, biofilm formation was reduced by ca. six logs, with no bacteria or fungi
detected on the tube segments. Because colonization of ETTs is polymicrobial, we also quantified
microbial growth from mixed species inocula (MRSA with PA01 and PA01 with C. auris). While
the duration of prevention of biofilm formation decreased in the presence of mixed species of
micro-organisms (Figure 6-4), the coated tubes continued to reduce or prevent colonization for
multiple days.
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Figure 6-3: Biofilms formed on ETT segments (5 mm) after the indicated number of days of incubation (daily
exchange of growth medium and re-inoculation). Measurements made in triplicate. Black bars: uncoated tube
segments; gray bars: coated segments. A: MRSA (BAA-41, 106 CFU inoculation). B: K. pneumoniae (ATCC 13883,
106 CFU inoculation). C: P. aeruginosa (ATCC 47085, 106 CFU inoculation). D: C. albicans (ATCC 90028, 103 CFU
inoculation). E: C. auris (CDC 0383, 103 CFU inoculation).

Figure 6-4: Mixed species biofilms formed on ETT segments (5 mm) after the indicated number of days of
incubation (daily exchange of growth medium and re-inoculation). Measurements made in triplicate. Black bars:
uncoated tube segments; gray bars: coated segments. A: MRSA (BAA-41, 106 CFU inoculation) with P. aeruginosa
(ATCC 47085, 106 CFU inoculation). B: P. aeruginosa (ATCC 47085, 106 CFU inoculation) with C. auris (CDC
0383, 103 CFU inoculation).
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To visualize biofilm formation and prevention thereof, we prepared samples for SEM.
Representative images are shown in Figure 6-5. C. auris (CDC 383) readily formed a stable biofilm
on uncoated ETT segments even though this organism has been reported to form less biofilm than
C. albicans 272. After 14 days of growth (with re-inoculation every 24 h), the fungal biofilm was
nearly completely covered with the extra-cellular matrix (Figure 6-5A), seen as a “cotton-like mass”
with C. albicans biofilm formation
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. At 14 days, the coated ETT surface showed no fungal

growth by SEM (Figure 6-5B). Culturing of adhered organisms indicated fungal colonization of
coated tubes by day 8 (approximately a three log reduction relative to controls, Figure 6-3E);
however, the populations of fungi adhered to coated tubes did not reach the levels of those adhered
to uncoated tubes through 14 days. The lack of fungi observed by SEM may be due to loss of
loosely adhered organisms on the coated tubes. Mixed species challenge of uncoated ETTs at 48
h with MRSA and PA01 showed biofilm formation in which both types of bacteria were readily
distinguishable (Figure 6-5C), while the coated segment remained uncolonized (Figure 6-5D).
Similarly, challenge of uncoated tube segments with a combination of PA01 and C. auris showed
biofilm formation with both organisms (Figure 6-5E); extensive colonization of Candida biofilms
by Pseudomonas has been observed

274

. There was no biofilm formation on the coated ETT

segment (Figure 6-5F).
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Figure 6-5: SEM images of ETT surfaces: A: biofilm of C. auris (CDC 383) on an uncoated tube after 14 days
(daily inoculation). B: surface of a coated tube after 14 days (daily inoculation with C. auris). C: mixed species
biofilm of MRSA and PA01 on an uncoated tube after 48 h. D: surface of a coated tube after 48 h (inoculation with
MRSA and PA01). E: mixed species biofilm of PA01 and C. auris on an uncoated tube after 48 h. F: surface of a
coated tube after 48 h (inoculation with PA01 and C. auris).

Inflammation, in response to endotoxin, is a primary cause of lung damage and other
deleterious responses to ventilator-associated infections

254-258

. The antimicrobial effects of the

ETT coating were expected to reduce the amount of endotoxin on the tubes and in the surrounding
growth media. To test this hypothesis, coated and uncoated ETT segments were exposed to P.
aeruginosa (PA01) in a nutrient medium for 24 h. To quantify endotoxin on tube surfaces, tubes
were removed from culture, gently rinsed with PBS to remove planktonic bacteria and sonicated
in neutralizing broth. Aliquots from the resulting broth were serially diluted and assayed for
endotoxin. Endotoxin amounts in the growth medium and on the tube segments are shown in
Figure 6-6. Concomitant with bacterial growth, endotoxin amounts increased in the presence of
uncoated tube segments, both on the segments and in the growth medium. In contrast, with the
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coated segments, endotoxin was substantially reduced in the growth medium and on the tube
segments.

Figure 6-6: Quantification of the amounts of endotoxin in the growth medium and on ETT segments after incubation
with P. aeruginosa for the indicated time periods. Black bars, uncoated tube segments. Grey bars, coated tube
segments.

To demonstrate the safety of the coated ETT, a GLP study of intubation in pigs was performed.
The animals were intubated and mechanically ventilated for 24 h, and to simulate a worst-case
scenario, test samples were manufactured with CSA-131(NDSA) in an amount 133% of the coated
ETTs described above. There was no mortality during the study, and the six treated pigs were
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humanely euthanized according to protocol at their scheduled endpoints of 24 h post treatment
(Table 6-2). The oropharyngeal area, trachea and lungs were grossly examined for abnormalities.
There were no significant macroscopic findings in these six animals. Histological analyses were
performed on lung and tracheal tissue. The test animals had no inflammation in the lungs while
the control animals had minimal inflammation in some sections (data not shown). The interstitial
edema seen in the lungs of both the test and control animals is considered not related to either
device but to the procedure and prolonged recumbency of the animals. The test animals had
increased cilia loss in the trachea compared to the control animals but it was not a significant
difference. In the trachea and in the lung, under the conditions of this study and based on the Irritant
Rank score, the test article was considered a non-irritant when compared to the control. To
determine if intubation with coated ETTs resulted in systemic exposure to CSA-131, blood
samples were taken and analyzed for CSA-131 at times between 0 and 24 h post intubation. Both
the controls and the test group had no detectable CSA found in the blood (detection limit of 5
ng/mL).
Table 6-2: CSA-131(NDSA) intratracheal repeat dose GLP study design.
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6.4

Conclusions
There is a pressing need for development of means of protecting medical devices from

microbial colonization, and this need is complicated by the continuous emergence of drug-resistant
pathogens. The broad-spectrum antimicrobial activities of the ceragenins, including activity
against drug-resistant bacteria and fungi, qualifies them as a potential solution to this need. Use of
a ceragenin to protect a medical device required optimization of coating method and composition;
full characterization of the coating involved study of ceragenin elution and protection of surfaces
from bacterial and fungal challenges; and demonstration of safety in a porcine intubation model.
These steps have been completed and the ceragenin-coated ETTs appear well suited for use in
preventing microbial colonization and reduction of inflammatory responses to bacteria and fungi
in intubated patients.
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Chapter 7

Antibacterial and antifungal activities of poloxamer micelles containing

ceragenin CSA-131 on ciliated tissues

7.1

1. Introduction
The broad-spectrum activity of ceragenins and AMPs is due primarily to the selective

association of these antimicrobials with bacterial and fungal membranes. For example, we have
shown that ceragenins bind to bacterial membrane surfaces even in the presence of larger surface
areas of mammalian cells

67

. This selectivity likely contributes to the antimicrobial activities of

ceragenin of many tissues, without adverse effects, including the peritoneal cavity
fractures 122, and on bone 119,120 and lung-associated

247

132

, in bone

medical devices.

With most bacterial and fungal pathogens, ceragenins display inhibitory activity at µg/mL
concentrations ; however, higher concentrations may be necessary to fully eradicate biofilm forms
of these organisms 93,275. In biofilm form, microorganisms enter a sessile state in which some cells,
including persister cells

276

, remain viable even after most other cells have been eradicated by

applied antimicrobials. Biofilms contribute to multiple diseases
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. For example, infections

associated with cystic fibrosis (CF) show substantial contributions from bacteria in biofilm form
278,279

. Substantial doses of antibiotics, including tobramycin, are used in an effort to suppress

bacterial growth, yet biofilms persist 278,280.
In the lungs of CF patients, bacterial biofilms accumulate along with DNA, F-actin, and
mucins. These compounds deactivate innate immune defenses, including AMPs, while ceragenins
remain active in their presence

63,103

. Consequently, ceragenins appear well suited for use in

reducing the biofilm burden in the CF lung. The presence of endogenous AMPs in the lungs 281
suggests that tissues in the lungs are tolerant of these antimicrobials, and the fact that a ceragenin-
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releasing endotracheal tube is well tolerated in vivo 247 suggests that the lung epithelium may also
be unaffected by ceragenins. However, while epithelial cells may remain viable, the cilia on these
cells, which play a critical role in maintaining lung health, are fragile and can be damaged by
antibiotics and mechanical insults. Consequently, evaluation of the potential use of ceragenins for
the eradication of biofilms must include observation of the impact of these antimicrobials on cilia
function. In initial experiments, we observed that the exposure of lungs and tracheal explants to
high concentrations of a ceragenin, CSA-131, led to decreases in cilia function. We therefore
sought methods to decrease the impact of this ceragenin on cilia, allowing the use of concentrations
of CSA-131 sufficient to eradicate biofilms without interfering with the essential role that these
cilia play.
Various poloxamers have been developed for use as drug carriers. The poloxamer Pluronic®
F127 (hereafter referred to as pluronic) has been especially well studied due to its abilities to form
well-defined micelles and sequester drugs for delivery to specific tissues

282

. In two previous

studies, it was observed that combinations of this non-ionic surfactant and ceragenins decreased
host cell cytotoxicity without substantially impairing antibacterial activities 80,108. The mechanism
of decreased toxicity is most likely due to transient encapsulation of ceragenins in micelles formed
by the pluronic. While ensconced in micelles, ceragenins are less prone to associate with host
membranes, yet the higher affinity of ceragenins for microbial membranes 67 and the dynamic
nature of micelles allow ceragenins to affect antimicrobial activities. In this manner, pluronic
micelles may act to amplify the membrane selectivity of ceragenins.
To observe the impact of pluronic micelles on ceragenins activity and to optimize ceragenin
formulation for use in treating biofilm-based infections in the lung, we studied the impact of a lead
ceragenin, CSA-131, with and without pluronic on cilia beating and the inhibition of bacterial and
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fungal growth in vitro and in tracheal and lung tissue explants. We found that the use of pluronic
with relatively high concentrations of CSA-131 leaves cilia beating intact, and the pluronic has no
impact on the antimicrobial activities of CSA-131. These results suggest that the formulation of
ceragenin CSA-131 in pluronic micelles may allow use of high concentrations of this antimicrobial,
sufficient to eliminate biofilms without negatively impacting cilia function.

7.2

Material and methods
Pluronic® F127, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide

and menadione were obtained from Sigma-Aldrich (St. Louis, MO, USA) and used as received.

7.2.1

Microbial cultures

S. aureus (ATCC 25923) and P. aeruginosa (ATCC 47085 (PA01)) were grown from fresh
colonies in trypticase soy broth (TSB) and incubated overnight at 37 °C. Fungal cultures, Candida
albicans (ATCC 90028) and Candida auris (CDC 0382, 0384, 0387, and 0389), were grown
overnight in sabouraud dextrose broth (SDB) or Roswell Park Memorial Institute medium (RPMI).
Cultures of bacteria and fungi were centrifuged, and pellets were washed three times with
phosphate buffered saline (PBS) and further resuspended in fresh PBS. Bacterial cultures were
diluted in TSB and fungal cultures were diluted in SDB or RPMI to 103 or 106 CFU/mL (optical
density (OD) readings at 600 nm).

7.2.2

Susceptibility testing in the presence or absence of pluronic

7.2.2.1 MIC
MICs were measured using the broth microdilution protocol described by the Clinical and
Laboratory Standards Institute

150

. Briefly, two-fold dilutions of CSA-131 were dispensed in
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separate wells of a 96-well plate. Aliquots (100 µL) of a prepared inoculum (106 CFU/mL for
bacteria and 103 CFU/mL for fungi) were added, and plates were incubated at 37 °C for 18–20 h.
Bacterial or fungal growth was visually observed to determine the MICs. Negative and positive
controls were included for each set of MIC measurements. For studies with pluronic, the surfactant
was added at 4% and 5% to the initial inocula in each experiment. Measurements were performed
in triplicate for all susceptibility tests.
7.2.2.2 Determination of antifungal and antibacterial susceptibilities of biofilms by XTT assay
Biofilm formation by selected bacterial and fungal strains was quantified by measuring
metabolic

activity

within

biofilms

using

2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-

tetrazolium-5-carboxanilide (XTT) 236. Biofilms were formed in 96-well plates and incubated for
48 h at 37 °C. After three washes with PBS to remove planktonic cells, CSA-131 (100 µg/mL) in
the presence or absence of 4% or 5% pluronic was added to the wells and incubated for 24 h. After
incubation, the wells were carefully washed with PBS. A solution of 10 mM menadione in 100%
acetone was added to an XTT solution (0.5 mg/mL) and mixed. An aliquot of the XTT/menadione
solution (100 µL) was added to each well. Each plate was then wrapped in aluminum foil and
incubated for 2–3 h at 37 °C. To prepare to read the optical density, aliquots of the supernatant (70
µL) were removed from each well. Using a microtiter plate reader, colorimetric changes were
measured at 490 nm. The percent of biofilm survival for each well containing CSA-131 with or
without pluronic was calculated in comparison to the biofilm formed in the absence of the
ceragenin (control).
7.2.2.3 Determination of minimum biofilm eradication concentrations (MBEC)
Inocula (106 CFU/mL) of bacterial and fungal strains (P. aeruginosa, S. aureus, C. albicans,
and C. auris) were incubated at 37 °C for 48 h in 1 mL of TSB or SDB in 96-well plates. Following
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incubation, the growth medium was gently removed, and wells were washed three times with
sterile PBS. CSA-131 (100 µg/mL), in TSB or SDB and in the presence or absence of pluronic (4%
or 5%), was added to the wells at concentrations ranging from 1 to 256 µg/mL, and each plate was
incubated at 37 °C for 24 h. Wells, including well edges, were scraped thoroughly with a plastic
spatula. Well contents were removed in 1 mL of neutralizing broth (Dey-Engley, Sigma–Aldrich)
and placed in a sonicating water bath (Fisher Scientific FS60, 42 kHz, 100 W, Pittsburg, PA, USA)
to disrupt biofilms. After 15 min, the resulting samples were serially diluted, and bacterial samples
were plated on TSA while fungal samples were plated on SDA. After 24 h or 48 h of incubation
at 37 °C, colonies were counted and MBECs were determined. The MBEC was defined as the
lowest concentration of antibiotic that prevented bacterial regrowth 283.
7.2.2.4 Measurement of kinetics of bactericidal and fungicidal activity
Cultures of S. aureus, P. aeruginosa, and C. albicans were prepared as described for MIC
measurements and placed in 96-well plates (106 CFU for bacteria and 103 CFU for fungi) with or
without CSA-131 (100 µg/mL), with or without pluronic (4%), in TSB (with bacteria) or SDB
(with fungi). Cultures were incubated at 37 °C. At 5, 15, 30, 60, and 120 min, aliquots were
removed from each well and added to neutralizing buffer to ensure that no further antibacterial
activity occurred. These samples were then serially diluted and plated on TSA or SDA. Cultures
were incubated at 37 °C for 24 h or 48 h, and colonies were counted and recorded.

7.2.3

Preparation of tracheal explants

Normal healthy porcine trachea and lung tissue was excised very fresh from slaughter. After
aseptic collection, whole tissues were transported in a 1:1 mixture of Dulbecco’s modified Eagle’s
medium (DMEM) and RPMI, which was pre-warmed and supplemented with penicillin-
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streptomycin-glutamine 100X (Hyclone, Logan, UT, USA). Explants were washed by tissue
immersion three to four times in warm, fresh DMEM/RPMI media. Explants were maintained by
continuous immersion in DMEM/RPMI media in a 5% CO2–95% air mixture in a humidified
incubator at 37 °C. Ethics statement: Trachea and lung materials were obtained from a local
butcher (Circle V meat Co., Spanish Fork, UT, USA) and were sourced from animals slaughtered
for human consumption; hence, ethical approval was not required for this research.

7.2.4

Latex bead clearance assay

Tracheas were washed and extra exterior tissues to the cartilage were removed. Tracheas were
opened and cut into approximately 2 × 1 cm explants consisting of the respiratory mucosa and
underlying cartilage. Explants were then immersed in different concentrations of CSA-131, with
and without pluronic, in the DMEM/RPMI mixture in 24-well plates for 1 h in a humidified
incubator at 37 °C with 5% CO2. Explants were then placed on small circular filter papers, which
were placed on top of 1% agarose gel plugs bathed in medium in 6-well plates. To determine cilia
activity on explants, epithelial surfaces were tested via a bead clearance assay 1 h post treatment
with CSA-131 (100 µg/mL), with or without pluronic (1%, 2%, 3%, 4%, and 5%). Five microliters
of a suspension of 1 µm diameter polystyrene microsphere beads (Polysciences, Inc., Warrington,
PA, USA) were pipetted on one edge of epithelial surfaces and evaluated for their complete
clearance (movement) across the surface with categorization of clearance in under 10 min, between
10 and 20 min, between 20 and 30 min, and no clearance (>30 min). Independent replicates were
completed for each time point. Outcomes were then counted and a percentage of clearance was
determined 284.
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7.2.5

SEM of cilia on porcine trachea

Explants (5 mm3) were washed gently in Sorensen buffer (0.1 M, pH 7.2) to remove mucus
and secretions. The fixative compounds were all diluted in the Sorensen buffer. The trachea pieces
were incubated for 24 h with 2% of glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA,
USA) at 4 °C and then rinsed five times in Sorensen buffer. Additional post-fixation was
performed using 1% of OsO4 (Electron Microscopy Sciences, Hatfield, PA, USA) for 1.5 h under
the hood at room temperature. After fixation, OsO4 was removed by rinsing the explants at least
seven times in Sorensen buffer and then explants were dehydrated in increasing concentrations of
ethanol: 10, 30, and 50, each step for 15–20 min. The process was completed inside critical dryer
baskets with 70% and 95% ethanol finishing with twice in 100% for 15–20 min. Samples were
then submerged in 100% ethanol in the critical point dryer at the critical point of carbon dioxide.
Prepared samples were mounted on aluminum stands and then sputter-coated with 5–10 nm of a
gold-palladium alloy and observed with SEM (FEI Helios NanoLab 600 SEM/FIB, Hillsboro, OR,
USA) at 5 kV.

7.2.6

Ex Vivo efficacy evaluation

Using 5 mm3 explant cubes of porcine trachea and lung, ex vivo antifungal efficacy
experiments were conducted. Cubes were dissected using a sterile razor blade form the ventral
surface of the left caudal lobe of three sets of porcine lungs 285. After trimming excess tissues away
from the explants to produce uniform of size (5 mm), explants were incubated at 37 °C in
DMEM/RPMI inoculated with 106 CFU/explant of C. auris (CDC 0384) or C. albicans (ATCC
90028) in a 48-well plate. Explants were treated after 2 h of incubation with CSA-131 in the
presence or absence of pluronic. Treated explants were incubated for 24 h at 37 °C. After
incubation, tissues were suspended in 250 µL of neutralizing broth and vortex on the highest
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setting for 4 min. Samples were then serially diluted in PBS, plated on 5% sheep blood TSA plates,
and incubated at 37 °C for 48 h 235.

7.3

Results and discussion
We initially determined the impact of pluronic, at 4% and 5% of the growth medium, on the

antibacterial and antifungal activity of ceragenin CSA-131. The amphiphilic nature of the
ceragenin makes it likely that it associates well with pluronic micelles. At issue is whether the
ceragenin can effectively escape micelles to exert antimicrobial effects. Earlier reports with
bacteria

80,108

demonstrated that pluronic did not substantially affect antibacterial activity. The

MICs and MBECs of CSA-131 alone and in the presence of pluronic at 4% and 5% are given in
Table 7-1. MBECs are the concentrations required to eliminate biofilms, including persister cells,
to detection limits. With both S. aureus and P. aeruginosa, MICs were unchanged in the presence
of pluronic, as observed previously. Notably, Candida spp., MICs were also unaffected by
pluronic, even though these are eukaryotic organisms. Notably, MBECs with both bacteria and
fungi were unchanged in the presence of pluronic. Results from studies given in Table 7-1 and a
previous study by Nagant et al. 93,108 suggest that a concentration of ceragenin of 100 µg/mL is
sufficient to eradicate established bacterial and fungal biofilms. Consequently, we used this
concentration as a target for antibacterial and antifungal activity, as well as in tolerability studies
with trachea and lung explants. A key preliminary question in these studies is whether the pluronic
alone has any effect on bacteria and fungi. To answer this question, the target concentration of
CSA-131 (100 µg/mL) was prepared with and without pluronic, and antibiofilm activity was
measured (Figure 7-1).
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Table 7-1: MICs of CSA-131 with bacteria and fungi in the absence or presence of pluronic.
MIC [MBEC] (µg/mL)
CSA-131

CSA-131 +
4% pluronic

CSA-131 +
5% pluronic

S. aureus
ATCC 25923

1 [100]

1 [100]

1 [100]

P. aeruginosa
ATCC 47085

2 [100]

2 [100]

2 [100]

C. auris
CDC 382

0.5 [82]

0.5 [82]

0.5 [82]

C. auris
CDC 384

0.5 [48]

0.5 [48]

0.5 [48]

C. auris
CDC 387

0.5 [64]

0.5 [64]

0.5 [48]

C. auris
CDC 389

0.5 [48]

0.5 [48]

0.5 [48]

C. albicans
ATCC 90028

0.5 [48]

0.5 [48]

0.5 [48]

Strains

In addition, established biofilms were exposed to pluronic alone.In these assays, biofilms were
generated over 48 h, and after treatment, bacterial and fungal counts were determined by plating
organisms freed from biofilms and counting colonies. Detection limits for the experiments were
two logs. At 100 µg/mL, with and without pluronic, CSA-131 lowered bacterial and fungal counts
to the detection limit (>four-log reduction (99.99% reduction)). Pluronic alone did not significantly
influence microbial counts from the biofilms.
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Figure 7-1: Antibiofilm results determined through the plating of microorganisms freed from biofilms,
culturing, and plate counting. White bars: S. aureus (ATCC 25923); black bars: P. aeruginosa (ATCC
47085); gray bars: C. albicans (ATCC 90028); hashed bars: C. auris (CDC 384). Detection limit: 2 logs. *
indicates p < 0.05 relative to controls and to pluronic alone.

To corroborate the antibiofilm data from counting bacterial and fungal colonies, a colorimetric
assay was performed to quantify biofilms remaining on surfaces after treatment. Results were
normalized to untreated controls (Figure 7-2). Significant decreases in biofilm were observed, but
differences between CSA-131 alone and with pluronic were not significant.

133

Figure 7-2: Antibiofilm results determined through colorimetric (XTT) assay represented as percent survival. White
bars: S. aureus (ATCC 25923); black bars: P. aeruginosa (ATCC 47085); gray bars: C. albicans (ATCC 90028);
hashed bars: C. auris (CDC 384). * indicates p < 0.05 relative to controls.

A possible consequence of the association of CSA-131 with pluronic micelles would be the
slowing of the kinetic antimicrobial activities of this ceragenin relative to the ceragenin alone. We
measured bacterial and fungal counts over time with CSA-131 (100 µg/mL) and CSA-131 with
pluronic (4%). Results from an experiment with P. aeruginosa (ATCC 47085) are shown in Figure
7-3.

Inocula of just over 106 CFU/mL were reduced to the detection limit within 15 min. At 5 min,

there was a small difference in bacterial counts with CSA-131 alone and CSA-131 with pluronic.
With S. aureus and with C. albicans, no significant differences between kinetic activity of the
ceragenin alone and with pluronic were observed Figure 7-3.
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Figure 7-3: Kinetic antibacterial activity against P. aeruginosa, MRSA, and C. albicans of CSA131 (100 _g/mL) (black squares), CSA-131 (100 _g/mL) with pluronic (4%) (black triangles);
untreated control (black diamonds). Detection limit was two logs.
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Having established the antibiofilm activity of CSA-131 in the presence of pluronic, we
determined the impact of formulations of CSA-131 on ciliated tissue explants from porcine
tracheas. The cilia on these tissues play a critical role in removing particulate matter from the lung
and trachea; consequently, it was important to establish that CSA-131 can exert antibacterial and
antifungal activity without damaging cilia. Furthermore, the presence of undamaged cilia is an
indication that the underlying epithelial and goblet cells are unaffected by ceragenin treatment. An
ex vivo assay was used to evaluate pluronic-containing formulations. In this assay the beating of
cilia can be actively observed. These observations were used to determine the concentration of
pluronic, with CSA-131 (100 µg/mL), that would prevent an impact on cilia function, and by
extension leave the underlying epithelial and goblet cells undamaged

285

. This method involves

sectioning porcine trachea which is supported in a nutrient medium, placing small beads on one
side of the explant, and measuring the transfer (clearance) of the beads to the other side of the
explants (Figure 7-4). In our hands, we could reproducibly measure bead clearance one hour after
sectioning and treatment. Twelve explants were used for each test condition, and the results are
reported as the number clearing beads in a given amount of time.

Figure 7-4: Description of methods used in harvesting and testing porcine trachea explants.
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With no treatment with CSA-131, all 12 explants cleared the applied beads within 20 min,
and 10 of the explants cleared the beads in less than 10 min (Table 7-1). Treatment of the explants
with CSA-131 at 100 µg/mL for one hour caused a majority (six of 12) to lose the ability to clear
the beads. Increasing amounts of pluronic (from 1 to 5%) restored the ability of the cilia to clear
the beads, and at 5% pluronic, bead clearance was the same as the control.
Table 7-2: Number of explants (out of 12) clearing beads during the indicated amount of time after incubation
with CSA-131 (100 µg/mL) for 1 h. The control was not treated with CSA-131. Indicated amounts of pluronic were
used with ceragenin.
Time Required for Bead Clearance
Pluronic

<10
min

<20
min

<30
min

No
Clearance

Control

10/12

2/12

-

-

0%

3/12

2/12

1/12

6/12

1%

4/12

2/12

1/12

5/12

2%

7/12

3/12

2/12

-

3%

7/12

4/12

1/12

-

4%

8/12

4/12

-

-

5%

10/12

2/12

-

-

To visualize the impacts of treatment of CSA-131, with and without pluronic, on cilia, we
obtained scanning electron microscope (SEM) images of explants that had been treated with CSA131 (100 µg/mL) alone and with pluronic (4%) (Figure 7-5). With the untreated explant, intact cilia
were observed without exposure of the underlying goblet or epithelial cells. In the image of the
explant treated with CSA-131 alone, exposed goblet cells were observed, suggesting that some
loss of cilia had occurred. This loss correlated with decreased cilia function in the bead clearance
assay. In contrast, with the explant treated with CSA-131 with pluronic (4%), a fully intact cilia
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Figure 7-5: SEM images of cilia on porcine trachea explants A: untreated, B: treated with CSA-131 at 100
µg/mL, and C: treated with CSA-131 at 100 µg/mL with 4% pluronic. Exposed goblet cells are circled in the image
from treatment with CSA-131 without pluronic.

bed was observed with no exposure of goblet or epithelial cells. This treatment did not influence
bead clearance, and it did not appear to influence the cilia bed. Dias et al. observed a similar loss
of cilia and concomitant exposure of goblet cells in canine trachea from intubated dogs 286.
We next verified that CSA-131, formulated with pluronic, was able to eradicate
microorganisms in tissue from the trachea and lung. For these studies, explants were infected with
either C. albicans or C. auris then treated with CSA-131 alone or with pluronic (4% or 5%). In
control explants, fungal counts were over six logs in both tissue types (Figure 7-6). From treated
explants, fungal counts were one and a half to two logs less (a decrease of up to 99%). Differences
from controls were statistically significant (p < 0.05), but small differences between results with
CSA-131 alone and CSA-131 with pluronic (4% or 5%) were not significant. Interestingly, there
was no significant difference of fungal growth in the tracheal and lung explants.
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Figure 7-6: Fungi remaining in tissue explants after incubation for two hours followed by treatment
with CSA-131 (with and without pluronic (4% or 5%) for one hour. Black bars: C. albicans (ATCC
90028); gray bars: C. auris (CDC 384). A: trachea explants; B: lung

7.4

Conclusions
Bacteria and fungi are both important pathogens in the trachea and lung, and infections are

increasingly recognized as polymicrobial. Consequently, effective development of new therapies
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should target a broad spectrum of bacteria and fungi. In addition, persistent infections, including
those associated with CF, involve biofilm components, which adds an antibiofilm component to
therapy development. AMPs play important roles in controlling microbial growth in these tissues;
however, it is evident that in some situations these innate immune defenses fail to fully protect the
trachea and lung. Considerations of means of augmenting the activities of AMPs are complicated
by the susceptibility of cilia to damage, and since they play vital roles in these tissues, potential
treatments must take into account impacts on cilia. Ceragenins have been shown to have potent
activity against pathogens associated with the trachea and lung, including the ability to eradicate
established biofilms. Nevertheless, concentrations of ceragenin CSA-131 necessary to eliminate
biofilms cause cilia damage. To mitigate these effects on cilia, we employed the poloxamer
Pluronic® F-127. The association of CSA-131 with micelles formed by this surfactant does not
alter antimicrobial activity against planktonic or biofilm forms of targeted microorganisms.
However, with pluronic, the impact of CSA-131 on cilia is abolished. Ex vivo studies of CSA-131
with pluronic demonstrate the ability of this ceragenin to substantially reduce numbers of
pathogenic strains of fungi in tissue. As a mimic of AMPs and with the protective effects of
pluronic, ceragenin CSA-131 appears to be well suited for the treatment of polymicrobial and
biofilm-related infections.
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